

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

A33606-PCT USA

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/647965

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/CA99/00314

07 April 1999

07 April 1998

TITLE OF INVENTION

HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS

APPLICANT(S) FOR DO/EO/US

HISCOTT, John and LIN, Rongtuan

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☒ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☐ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

A postcard.

Express Mail No. : EK839862405US

Date of Deposit: 6 October 2000

U.S. APPLICATION NO. (IF KNOWN) 37 CFR 09/647965	INTERNATIONAL APPLICATION NO. PCT/CA99/00314	ATTORNEY'S DOCKET NUMBER A33606-PCT USA
--	--	---

21. The following fees are submitted:				CALCULATIONS PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :					
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1,000.00					
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00					
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$710.00					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$690.00					
<input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00					
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$860.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	107 - 20 =	87	x \$18.00	\$1,566.00	
Independent claims	4 - 3 =	1	x \$80.00	\$80.00	
Multiple Dependent Claims (check if applicable).				<input checked="" type="checkbox"/>	\$270.00
TOTAL OF ABOVE CALCULATIONS =				\$2,776.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable).				<input checked="" type="checkbox"/>	\$1,388.00
SUBTOTAL =				\$1,388.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$1,388.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).				<input type="checkbox"/>	\$0.00
TOTAL FEES ENCLOSED =				\$1,388.00	
				Amount to be: refunded	\$
				charged	\$

- ☐ A check in the amount of _____ to cover the above fees is enclosed.
- ☒ Please charge my Deposit Account No. **02-4377** in the amount of **\$1,388.00** to cover the above fees.
A duplicate copy of this sheet is enclosed.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **02-4377** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Rochelle K. Seide, Ph.D.
BAKER BOTTS LLP
30 Rockefeller Plaza
New York, NY 10112-0228

Rochelle K. Seide
SIGNATURE

Rochelle K. Seide, Ph.D.

NAME

32,300

REGISTRATION NUMBER

6 October 2000

DATE

A33606-PCT USA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicants : HISCOTT, John et al.
Serial No. : To be assigned
Filed : April 7, 1999
For : HIGHLY ACTIVE FORMS OF INTERFERON
REGULATORY FACTOR PROTEINS

EXPRESS MAIL CERTIFICATION

Express Mail Mailing No. EJ839862405US

Date of Deposit - October 6, 2000

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to: Box PCT, Assistant Commissioner for Patents, Washington, D.C., 20231.


Signature of person mailing
correspondence

Name of person mailing correspondence: LOUIS LAFFITTE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : HISCOTT, John et al.
Serial No. : To be assigned
Filed : 07 April 1999
For : HIGHLY ACTIVE FORMS OF INTERFERON
REGULATORY FACTOR PROTEINS

Express Mail Mailing No. EK83996330US

PRELIMINARY AMENDMENT

Assistant Commissioner of Patent
Box PCT
Washington, D.C., 20231

Sir or Madam:

Prior to examination of the above-identified application, please make the following amendments:

IN THE CLAIMS:

Please cancel Claims 28 to 31 without prejudice.

Claim 5, Line 25: please delete "to 4" and substitute therefor --or 2--.

Claim 6, Line 2: please delete "to 4" and substitute therefor --or 2--.

Claim 23, Line 8: please delete "The nucleotide sequence according to claim 22, having" and substitute therefore --A nucleotide sequence comprising--.

Claim 24, Line 11: please delete "The nucleotide sequence according to claim 22, having" and substitute therefore --A nucleotide sequence comprising--.

Claim 25, Line 14: please delete "The nucleotide sequence according to claim 22, having" and substitute therefore --A nucleotide sequence comprising--.

Claim 26, Line 19: please delete "to 21" and substitute therefor --or 2--.


Claim 34, Line 21: please delete "to 21" and substitute therefor--or 2--.

REMARKS

Favorable consideration and allowance of all pending claims is respectfully requested.

Respectfully submitted,

BAKER BOTTS LLP



Rochelle K. Seide

Reg. No. 32,300

Attorney for the Applicant

Tel. (212) 705-5000

Dated: October 6, 2000

HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINSBACKGROUND OF THE INVENTION

Interferons (IFNs) are a large family of multifunctional secreted proteins involved in antiviral defence, cell growth regulation and immune activation (63). Virus infection induces the transcription and synthesis of multiple IFN genes (33,52,63); newly synthesized IFN interacts with neighbouring cells through cell surface receptors and the JAK-STAT signalling pathway, resulting in the induction of over 30 new cellular proteins that mediate the diverse functions of the IFNs (17,35,39,58). Among the many virus- and IFN-inducible proteins are the growing family of IRF transcription factors, the Interferon Regulatory Factors (IRFs).

IRF-1 and IRF-2 are the best characterized members of this family, originally identified by studies of the transcriptional regulation of the human IFN- β gene (22,23,30,47). Their discovery preceded the recent expansion of this group of IFN-responsive proteins which now include seven other members: IRF-3, IRF-4/Pip/ICSAT, IRF-5, IRF-6, IRF-7, ISGF3 γ /p48 and ICSBP (48). Structurally, the Myb oncoproteins share homology with the IRF family, although its relationship to the IFN system is unclear (62). Recent evidence also demonstrates the presence of virally encoded analogue of cellular IRFs - vIRF in the genome of human herpes virus 8 (HHV8) (55).

The presence of IRF-like binding sites in the promoter region of the IFNA and IFNB genes implicated the IRF factors as essential mediators of the induction of IFN genes. The original results of Harada et al. (30,32) indicated that IFN gene induction was activated by IRF-1, while the related IRF-2 factor suppressed IFN expression. However, the essential role of IRF-1 and IRF-2 in the regulation of IFNA and IFNB gene expression has become controversial with the observation that mice containing homozygous deletion of IRF-1 or IRF-2, or fibroblasts derived from these mice, induced IFNA and IFNB gene

expression after virus infection to the same level as the wild-type mice or cells (44).

On the other hand, IRF-1 was shown to have an important role in the antiviral effects of IFNs (44,54). IRF-1 binds to the ISRE element present in many IFN-inducible gene promoters and activates expression of some of these genes (54). However, activation of ISG genes by IFNA and IFNB was shown to be mediated generally by the multiprotein ISGF3 complex (31,36,38). The binding of this complex to DNA is mediated by another member of the IRF family, ISGF3 γ /p48, which in IFN-treated cells interacts with phosphorylated STAT1 and STAT2 transcription factors forming the heterotrimeric complex ISGF3 (8,39,62). The homozygous deletion of p48 in mice abolished the sensitivity of these mice to the antiviral effects of IFNs, and virus-infected macrophages from p48 $^{-/-}$ mice showed an impaired induction of IFNA and IFNB genes (31).

Several other members of the IRF family have been identified. The ICSBP gene is expressed exclusively in the cells of the immune system (18,64) and its expression can be enhanced by IFN γ . ICSBP was shown to form a complex with IRF-1 and inhibit the transactivating activity of IRF-1 (9,59). The homozygous deletion of ICSBP in mice leads to defects in myeloid cell lineage development and chronic myelogenous leukemia (34). Another lymphoid specific Pip/LSIRF/IRF-4 was identified (19,43,66) that interacts with phosphorylated PU.1, a member of the Ets family of transcription factors (15). The Pip/PU.1 heterodimer can bind to the immunoglobulin light chain enhancer and function as a B cell specific transcriptional activator. Expression of Pip/LSIRF was induced by antigenic stimulation but not by IFN, and Pip/LSIRF/IRF-4 $^{-/-}$ mice failed to develop mature T and B cells (46). A novel member of the IRF family was recently identified by its ability to bind to an ISRE-like element in the promoter region of the Qp gene of EBV (69).

Another unique member of the human IRF family, IRF-3 was characterized recently (2). The IRF-3 gene encodes a 55-kDa protein which is expressed constitutively in all tissues. IRF-3 was originally identified as a member of the

IRF family based on homology with other IRF family members and on binding to the ISRE of the ISG15 promoter. The relative levels of IRF-3 mRNA do not change in virus-infected or IFN-treated cells. Recombinant IRF-3 binds to the ISRE element of the IFN-induced gene ISG-15 and stimulates this promoter in transient expression assays. In previous studies, it has been shown that IRF-3 binds to the IE and PRDIII regions of the IFNA and IFNB promoters respectively, but has different effects on their transcriptional activity (56). While the induction of the IFNA4 promoter activated by IRF-1 or virus infection was inhibited in the presence of IRF-3, the fusion protein containing the IRF-3 DNA binding domain and the RelA(p65) transactivation domain effectively activated both IFNA and IFNB promoters. In contrast, co-expression of IRF-3 and RelA plasmids transactivated the IFNB gene promoter, but not the promoter of the IFNA4 gene (56).

Most of the IRF family members so far identified appear to have specific and critical functions in lymphoid cells and/or their action is related to the signalling pathway induced by IFN or viruses. Interestingly, there is recent evidence indicating that the IRF(s) may also play a role in the transcriptional activation of viral promoters. The Qp promoter region of the EBV-encoded gene EBNA-1 contains an ISRE-like element that is responsive to the IRF-1 and IRF-2 as well as to IFN- α . Using a yeast one-hybrid screen technique, a new factor was recently isolated that binds specifically to the Qp ISRE. The amino acid sequence of this protein is identical to the IRF-7 protein present in the Genbank database ((69); accession number U73036). By homology search of the HGF ETS cDNA library the Pitha group has also identified a novel IRF whose sequence is identical to that of IRF-7. At the amino acid level, IRF-7 shows highest homology to IRF-3. Several open reading frames (ORFs) of IRF-7 have been identified. Pagano's group found three shorter ORFs, listed in the database as IRF-7A, B and C ((69), accession nos. U53830, U53831 and U53832, respectively). A new IRF-7 isoform, IRF-7H, was recently identified by Pitha's group ((70), accession number AF076494).

In vitro translated IRF-7 encodes a protein of 68 kDa (69, 72). Interestingly, while in vitro translated IRF-7 protein binds effectively to the Qp ISRE, it doesn't seem to affect transcription of Qp-driven reporter constructs in a transient transcription assay (72). In contrast to IRF-3, IRF-7 expression is not generally constitutive but can be effectively induced by IFN- α in fibroblast cells, B-cells and other cells of lymphoid origin (70, 71). Like IRF-3, in uninfected cells, IRF-3 is present mainly in the cytoplasm, virus infection induced phosphorylation of IRF-7, resulting in cytoplasmic to nuclear translocation of phosphorylated IRF-7 and activated gene transcription (70, 71). Recent studies indicate that virus-stimulated phosphorylation of IRF-3 results in the activation of IFN α 4 and IFN β gene transcription in murine cells. Once produced and secreted from the infected cell, IFN α 4 and IFN β subsequently feed back on cells through the IFN receptor, stimulate the Jak-STAT pathway and lead to the IFN-responsive activation of another member of the IRF family - IRF-7; up-regulation of IRF-7 production then mediates the induction of non-IFN α 4 gene expression (71).

SUMMARY OF THE INVENTION

The present invention relates to IRF proteins that have been modified in the carboxy-terminus domain (transactivation domain) by modification of serine and/or threonine sites. Modification may be achieved by phosphorylation of serine and/or threonine, or by replacement of serine and/or threonine residues with residues having acidic side-chains, preferably carboxylic acid-containing side-chains, such as aspartic acid or glutamic acid residues. Such modified proteins may be mutants of IRF-3 and IRF-7, including chimeric proteins having portions of both IRF-3 and IRF-7, and post-translationally modified (phosphorylated) IRF-3 protein, the phosphorylation being induced by Sendai virus infection.

More specifically, the present invention provides a modified interferon regulatory factor (IRF) protein, the protein comprising at least one modified serine or threonine

M 05.05.00

5

phosphoacceptor site in the carboxy-terminus domain, preferably wherein cytokine gene activation by the modified IRF is increased relative to cytokine gene activation by a corresponding wild type IRF protein.

5 The present invention also provides nucleotide sequences which encode a protein of the invention as described above. Such nucleotide sequences may, for example, be used to modify a target cell of an organism.

10 The present invention also provides a pharmaceutical composition comprising an effective amount of the interferon regulatory factor (IRF) protein according to the invention, together with a pharmaceutically acceptable carrier, for the treatment of a viral infection, for example, an influenza infection, a herpes infection, a hepatitis infection or an HIV
15 infection.

The present invention also provides a commercial package containing the IRF protein or pharmaceutical composition according to the invention, together with instructions for its use for the treatment of cancer or of a
20 viral infection, for example, an influenza infection, a herpes infection, a hepatitis infection or an HIV infection.

The present invention further provides use of the interferon regulatory factor (IRF) protein according to the invention to activate a cytokine gene, preferably wherein the
25 cytokine gene is an interferon gene or a chemokine gene.

DESCRIPTION OF THE FIGURES

Figure 1. Sendai virus infection induces IRF-3 degradation. IRF-3 expression plasmid CMVBL-IRF3 (lanes 1 and 2) or CMVBL vector alone (lanes 3 and 4), both at
30 5 µg were transiently transfected into 293 cells by the calcium

76023-19

M 05:05:00

5a

phosphate method. At 24h post transfection, cells were infected with Sendai virus for 16h (lanes 2 and 4) or left uninfected (lanes 1 and 3). Whole cell extracts (20 μ g) were prepared and analyzed by immunoblotting with anti-IRF-3 antibody.

Figure 2. Sendai virus induced phosphorylation and degradation of IRF-3 protein. A) rtTA-IRF-3 cells, selected as described in Example, were induced to express IRF-3 by doxycycline treatment for 24h. At 24h after Dox addition, cells were infected with Sendai virus for 4, 8, 12, 16, 20, or 24h (lanes 2-7) or were left uninfected (lane 1). IRF-3 protein was detected in whole cell extracts (10 μ g) by immunoblot. Two forms of IRF-3 were detected, designated as form I and form II. B) At 24h post Dox induction, rtTA-IRF-3 cells were infected with Sendai virus for 16 hours (lanes 4-8) or were left uninfected (lanes 1-3). Whole cell extracts from untreated

cells (20 μ g) or Sendai virus infected cells (60 μ g) were incubated with 0.3 units of potato acidic phosphatase (PPA, lanes 2, 3, 7 and 8) or 5 units of calf intestinal alkaline phosphatase (CIP, lanes 4 and 5) in the absence (lanes 1, 2, 4, 6 and 7) or presence of phosphatase inhibitors (lanes 3, 5 and 8). Phosphorylated IRF-3 protein appears as a distinct band in immunoblots, migrating more slowly than IRF-3 forms I and II.

Figure 3. Analysis of IRF-3 deletion mutants in Sendai virus induced phosphorylation.

- 10 (A) Schematic representation of four IRF-3 deletions. Thick solid lines and thin dashed lines indicate included and excluded sequences, respectively. The N-terminal IRF homology domain, the nuclear export signal (NES) and C-terminal IRF association domain are indicated.
- 15 (B) Expression plasmids (5 μ g each) encoding wild type and deletion mutants of IRF-3 (as indicated above the lanes) were transiently transfected into 293 cells; at 24h post transfection, cells were infected with Sendai virus for 16h (lanes 2, 4, 6, 8, and 10) or left uninfected (lanes 1, 3, 5, 7, and 9). Whole cell extracts (20 μ g) were prepared from infected and control cells and analyzed by immunoblotting for IRF-3 forms I and II and for the presence of phosphorylated IRF-3 (P-IRF-3) with anti-IRF-3 antibody.

25 Figure 4. Analysis of IRF-3 point mutations in Sendai virus induced phosphorylation.

- (A) Schematic representation of IRF-3 point mutations. Thick solid lines and thin dashed lines indicate included and excluded sequences, respectively. The N-terminal IRF homology domain, the Nes element and C-terminal IRF association domain are indicated. Amino acids residues from 382 to 414 and from 141 to 147 are shown. The amino acids targeted for alanine or aspartic acid substitution are shown in large print. The point mutations are indicated below the sequence: (2A: S396A/S398A; 3A: S402A/T404A/S405A; 5A: S396A/S398A/S402A/T404A/S405A); 5D S396D/S398D/S402D/T404D/S405D; J2A: S385A/S386A; NES: S145A/S146A).
- 35

(B) Expression plasmids (5 μ g each) encoding wild type and

point mutants of IRF-3 (as indicated above the lanes) were transiently transfected into 293 cells; at 24h post transfection, cells were infected with Sendai virus for 16h (lanes 2, 4, 6, 8, 10, 12, 14, 16 and 18) or left uninfected (lanes 1, 3, 5, 7, 9, 11, 13, 15 and 17). Whole cell extracts (20 μ g) were prepared from infected and control cells and analyzed by immunoblotting for IRF-3 forms I and II and for the presence of phosphorylated IRF-3 (P-IRF-3) with anti-IRF-3 antibody.

Figure 5. Virus dependent cytoplasmic-nuclear translocation of IRF-3.

The subcellular localization of the GFP-IRF-3 (A and B), GFP-IRF-3(5A) (C and D), GFP-IRF-3(5D) (E and F) and GFP-IRF-3(NES) (G and H) was analyzed in uninfected (A, C, E, and G) and Sendai virus infected COS-7 cells at 16h after infection. GFP fluorescence was analyzed in living cells with a Leica fluorescence microscope using 40x objective.

Figure 6. Transactivation of PRDI/PRDIII and ISRE containing promoters by IRF-3.

293 cells were transfected with IFN β -CAT (A and B) or ISG15-CAT (C) reporter plasmids and the various expression plasmids as indicated below the bar graph. CAT activity was analyzed at 48h post-transfection with 100 μ g (IFN β -CAT) or 10 μ g (ISG15-CAT) of total protein extract for 1-2h at 37°C. Relative CAT activity was measured as fold activation (relative to the basal level of reporter gene in the presence of CMV-B1 vector alone after normalization with co-transfected β -Gal activity); the values represent the average of three experiments with variability shown in the error bar.

Figure 7. IRF-3 inducible expression of RANTES gene.

(A) Stimulation of RANTES gene transcription in virus-infected and IRF-3(5D)-expressing cells. The rtTA, IRF-3 and IRF-3(5D) cells were cultured in the presence or absence of Dox as indicated. After 30 hours, cells were either left untreated, infected with Sendai virus (80HAU/ml) for 16 hours, or treated with IFN- α/β (100 IU/ml). The neutralizing antibody for type I IFN (Sigma) was added at the time of Dox addition.

Total RNA was isolated from each sample and analyzed by RPA using the hCK5 kit (Pharmingen).

(B) Repression of virus-induced RANTES gene transcription by a dominant-negative form of IRF-3. The rtTA- and

5 IRF-3(Δ N)-expressing cells were either left untrated or infected with Sendai virus (80 HAU/ml) for 16 hours. Total RNA was isolated from each sample and analyzed by RPA.

(C) The kinetics of RANTES expression induced by IRF-3 (5D). Total RNA from IRF-3(5D)-expressing cells was isolated
10 from each sample after Dox addition and analyzed by RPA.

(D) Cell culture supernatants were analyzed for the presence of RANTES protein by an ELISA performed as specified by the manufacturer (Biosource International).

Figure 8. Stabilization of IRF-3 by proteasome
15 inhibitors.

IRF-3 Δ N (Δ 9-133) (B) or IRF-3 Δ N2A (C) expression plasmids were transiently transfected into 293 cells; at 24h post transfection, cells were infected with Sendai virus and treated for 12h with calpain inhibitor I (100 μ M, lanes 2 and
20 5) or MG132 proteasome inhibitor (40 μ M, lanes 3 and 6). Ethanol, the solvent for calpain inhibitor I and MG132, was added to the cells as control (lanes 1 and 4). Endogenous (A) and transfected (B and C) IRF-3 proteins were detected in whole cell extracts (20 μ g) by immunoblot.

25 Figure 9. IRF-3 interacts with CBP in virus infected cells.

(A) Schematic representation of CBP, illustrating the domains involved in interaction with host or viral proteins (modified from (28)) and the myc-tagged CBP proteins (CBP1,
30 CBP2, CBP3) used for immunoprecipitation.

(B) 293 cells were transfected with wild type and deletion mutants of IRF-3 expression plasmid (5 μ g, as indicated above the lanes) or left untransfected (lanes 1 and 8). At 24h after transfection, cells were infected with Sendai virus for 16h
35 (lanes 1, 3-8, and 10-13) or left uninfected (lanes 1 and 9). Whole cell extracts (300 μ g, except lane 1, which was 600 μ g) were immunoprecipitated with anti-CBP antibody A22 (lanes 1-6)

or with preimmune serum (lane 7). The immunoprecipitated complexes (lanes 1-7) or 30 μ g whole cell extracts (lanes 8-13) were run on 5% SDS-PAGE and subsequently probed with anti-IRF-3 antibody.

- 5 (C) 293 cells were co-transfected with myc-tagged CBP expression plasmids (as indicated above the lanes) and IRF-3 Δ N (Δ 9-133) expression plasmid. At 24h after transfection, cells were infected with Sendai virus (lanes 2, 4 and 6) or left uninfected (lanes 1, 3 and 5). Whole cell extracts (300 μ g)
- 10 were immunoprecipitated with monoclonal anti-myc-tag antibody 9E10. The immunoprecipitated complexes were run on 5% SDS-PAGE and different forms of IRF-3 in the precipitates were analyzed by immunoblotting with anti-IRF-3 antibody.

- (D) Whole cell extracts (30 μ g) from (C) were also
- 15 analyzed directly for the expression of myc-tagged CBP proteins by immunoblotting using anti-myc antibody 9E10.

Figure 10. The cDNA sequence encoding IRF-3(5D), together with the amino acid sequence of IRF-3(5D).

- Figure 11. Transactivation study as described in
- 20 Figure 6, using the IFN β -CAT reporter plasmid to indicate the activity of various forms of IRF-3 and IRF-7 and binary mixtures thereof.

Figure 12. The cDNA sequence encoding IRF-7A(2D), together with the amino acid sequence of IRF-7A(2D).

- 25 Figure 13. The cDNA sequence encoding the IRF-7(1-246)/IRF-3(5D)(132-427) chimeric protein, together with the amino acid sequence of the IRF-7(1-246)/IRF-3(5D)(132-427) chimeric protein.

- Figure 14. Transactivation study as described in
- 30 Figure 6, using the IFN β -CAT reporter plasmid to indicate the relative activity of various forms of IRF-3 and IRF-7, binary mixtures thereof and the chimeric protein IRF-7(1-246)/IRF-3(132-427) (IRF-7N-IRF-3(5D)C in Figure 14).

DETAILED DESCRIPTION OF THE INVENTION

- 35 As used herein, the term "nucleotide sequence" means a DNA or RNA molecule or sequence, and can include, for

example, a cDNA, genomic DNA, or synthetic DNA sequence, a structural gene or a fragment thereof, or an mRNA sequence, that encodes an active or functional polypeptide.

Two DNA, RNA or polypeptide sequences are

- 5 "substantially homologous" or "structurally equivalent" when there is at least about 85% (preferably at least about 90%, more preferably at least about 95%) identity between the nucleotides or amino acids over a defined length of the molecule. DNA sequences that are substantially homologous can
10 be identified in a Southern hybridization experiment under, for example, stringent conditions, as defined for that particular system. Appropriate hybridization conditions are within the knowledge of a person skilled in the art. See, for example, Maniatis et al., Molecular Cloning, A Laboratory Manual. Cold
15 Spring Harbour Laboratory, New York (1982); Brown, T. A., Gene Cloning: An Introduction (2nd Ed.) Chapman & Hall, London (1990).

- The results disclosed herein show that phosphorylation represents an important post-translational
20 modification of IRF-3 leading to cytoplasmic-to-nuclear translocation of phosphorylated IRF-3, stimulation of DNA binding and transcriptional activity, association of IRF-3 with the transcriptional co-activator CBP/p300, and ultimately proteasome mediated degradation.

- 25 More specifically, the results disclosed herein show that, following Sendai virus infection, IRF-3 may be post-translationally modified by protein phosphorylation at multiple serine and threonine residues, located in the carboxy-terminus of IRF-3.

- 30 Furthermore, while modification of functionally relevant (phosphoacceptor) serine and threonine sites may be by phosphorylation, the modification may also be a mutation represented by replacement of at least one of these functionally relevant serine or threonine residues with an
35 amino acid having a carboxylic acid in its side chain, preferably aspartic acid or glutamic acid, more preferably aspartic acid. The preferred mutant form of IRF-3 is that

M 05.05.00

11

having aspartic acid residues in at least one of positions 396, 398, 402, 404 and 405 of the sequence, more preferably in positions 396, 398, 402, 404 and 405 of the sequence (IRF-3(5D)) (Figure 10). The preferred mutant form of IRF-7 is that having asparatic acid residues in at least one of positions 477 and 479 of the sequence, more preferable in positions 477 and 479 of the sequence (IRF-7(2D)) (Figure 12).

Also within the scope of the invention are chimeric proteins comprising a carboxy-terminus domain of one modified IRF protein, modified as discussed above, and an amino-terminal domain of another IRF protein. Preferably, the amino-terminus of IRF-7 is fused to the carboxy-terminus of modified IRF-3. It is more preferred that the carboxy-terminus of modified IRF-3 is that of IRF-3(5D). Even more preferred is a chimeric protein comprising residues 1 to 246 of IRF-7 and residues 132 to 427 of IRF-3(5D) (Figure 13).

Also within the scope of the invention are proteins which are substantially homologous to the above proteins and which retain the function of those proteins. This includes proteins based on human IRF-3 and IRF-7, as well as corresponding IRF-3 and IRF-7 proteins of other species.

Nucleotide sequences within the scope of the invention are those which encode a protein of the invention. Preferably, the nucleotide sequence is a coding DNA sequence as defined in Figure 10 or a DNA sequence which is hybridizable under stringent conditions with the complement of the coding DNA sequence of Figure 10, which DNA encodes IRF-3(5D). Also, preferably, the nucleotide sequence is a coding DNA sequence as defined in Figure 12 or a DNA sequence which is hybridizable under stringent conditions with the complement of the coding DNA sequence in Figure 12, which DNA encodes IRF-7(2D). Also

76023-19

M 05.05.00

11a

ART 34 AMDT

preferably, the nucleotide sequence is a coding DNA sequence as defined in Figure 13 or a DNA sequence which is hybridizable under stringent conditions with the complement of the coding DNA sequence of Figure 13, which DNA encodes IRF-5 7(1-246)/IRF-3 (132-427) chimeric protein.

A combination of IRF-3 deletion and point mutations localized the inducible phosphorylation sites to the region -ISNSHPLSLTSDQ- between amino acids 395 and 407; point mutation

T 05.05.00

of Ser-396 and Ser-398 residues eliminated virus-induced phosphorylation of IRF-3 protein, although residues Ser-402, Thr-404 and Ser-405 were also targets. Phosphorylation results in the cytoplasmic to nuclear translocation of IRF-3, DNA binding and increased transcriptional activation. Substitution of the Ser/Thr sites with the phosphomimetic Asp generated a constitutively active form of IRF-3 that functioned as a very strong activator of promoters containing PRDI/PRDIII or ISRE regulatory elements. Use of phosphomimetic Glu for this purpose is also possible. Phosphorylation also appears to represent a signal for virus mediated degradation, since the virus induced turnover of IRF-3 was prevented by mutation of the IRF-3 Ser/Thr cluster or by proteasome inhibitors.

Interestingly, virus infection resulted in the association of IRF-3 with the CBP coactivator, as detected by co-immunoprecipitation with anti-CBP antibody, an interaction mediated by the C-terminal domains of both proteins. Mutation of the residues Ser-396 and Ser-398 in IRF-3 abrogated its binding to CBP. These results are discussed in terms of a model in which virus-inducible C-terminal phosphorylation of IRF-3 alters protein conformation to permit nuclear translocation, association with transcriptional partners and primary activation of IFN- and IFN-responsive genes.

Sendai virus dependent phosphorylation of IRF-3 was detected, occurring in a cluster of Ser and Thr sites in the carboxyl-terminal end of the protein. The residues implicated in this regulatory phosphorylation event are Ser-396/Ser-398/Ser-402/Thr-404/Ser-405, particularly the Ser-396/Ser-398 amino acids. 2) Phosphorylation of the IRF-3 in the Ser-Thr cluster resulted in the cytoplasmic to nuclear translocation of IRF-3; nuclear translocation was blocked by mutation of the phosphorylated amino acids. 3) Sendai virus infection induced the DNA binding and transactivation potential of IRF-3. Furthermore, IRF-3 containing the phosphomimetic Asp at the sites of C-terminal phosphorylation was an exceptionally strong transactivator of PRDI/PRDIII and ISRE containing promoters. 4) Phosphorylation was also required for the

association of IRF-3 with the CBP co-activator protein. 5)
Sendai virus infection resulted in IRF-3 degradation; again,
phosphorylation was required as a signal for inducer mediated
degradation since mutation of Ser/Thr cluster also blocked
5 virus induced degradation.

Cytoplasmic to nuclear translocation of IRF-3 as a
consequence of virus infection was inhibited by mutation of the
Ser/Thr cluster, indicating an important regulatory role for
C-terminal phosphorylation in the activation of IRF-3. Also
10 strikingly, the conversion of the phosphorylation sites to the
phosphomimetic Asp altered the subcellular localization of
IRF-3 in uninfected cells. A proportion of IRF-3(5D) was
localized to the nucleus of uninfected cells, suggesting that
some IRF-3 may shuttle to and from the nucleus constitutively;
15 this observation is consistent with the identification of a
nuclear export signal in IRF-3. Mutation of L144A/L145A in the
NES element produced the most impressive alterations in
subcellular localization. In uninfected cells, IRF-3 was
partitioned in both the nucleus and cytoplasm; virus infection
20 changed the nuclear pattern of staining from extra-nucleolar
homogeneous staining as observed for wtIRF-3 to an intense
nuclear speckling. At this stage, the nature of the subnuclear
changes in IRF-3 localization are not explained, although it is
possible that IRF-3(NES) translocates efficiently into the
25 nucleus but becomes trapped in the nuclear pore complex during
the export process.

One of the striking results of the mutagenesis of the
C-terminal domain of IRF-3 was the generation of IRF-3(5D), an
exceptionally strong activator of IFN- β and ISG-15 gene
30 expression. The phosphomimetic form of IRF-3 alone was able to
stimulate IFN- β expression as strongly as virus infection, a
level of stimulation not previously observed in co-expression
experiments (24,61). In previous experiments, it has been
demonstrated that IRF-3 was able to bind the ISRE element of
35 ISG-15, as well as the PRDIII/PRDI and IE regions of the IFNB
and IFNA promoters, respectively (2,56). Virus induction
results in the appearance of two new protein-DNA complexes;

supershift experiments confirmed that both complexes contain IRF-3; it is not clear at this stage whether the upper complex also contains other proteins such as in the VIC (10,29) and DRAF (16) complexes or whether the lower complex represents a breakdown product of IRF-3. Strikingly, the same complexes appeared following co-transfection of IRF-3(5D) expression plasmid in the absence of virus induction, indicating that IRF-3(5D) represented a constitutive DNA binding form of IRF-3. Thus, in uninfected cells, IRF-3(5D) localized in part to the nucleus (Fig. 5), interacted with DNA constitutively and was a strong activator of gene expression (Fig. 6).

The recent crystal structure of the related IRF-1 protein bound to PRDI provides evidence for a novel helix-turn-helix motif that latches onto a GAAA core sequence via three of the five conserved tryptophan amino acids of the DNA binding domain (20). By analogy with IRF-3, two GAAANN sequences present in PRDIII of IFN- β and another GAAANN element present in PRDI may serve as DNA contacts for multiple IRF-3(5D) proteins with strong activating potential. Similarly, the ISRE element of the ISG-15 promoter also contains several GAAANN anchors for potential IRF binding. Given the range of promoters that possess this hexameric sequence (48), it will be of interest to determine the capacity of IRF-3(5D) to stimulate expression of different cytokine and chemokine genes.

IRF-3 joins a growing list of cellular and viral proteins that functionally interact with CBP/p300 proteins, highly homologous proteins originally identified through their interactions with adenovirus E1A and CREB proteins (1,13). As a critical determinant of its global transcriptional coactivator activity, CBP/p300 possesses histone acetyltransferase activity (5,50). Acetylation of histones is involved in the destabilization and remodelling of nucleosomes, a crucial step in permitting the accessibility of transcriptional factors to DNA templates. Several studies have now demonstrated that CBP/p300 participates in the transcriptional process by providing a scaffold for different

classes of transcriptional regulators on specific chromatin domains (12,50). A growing body of biochemical and genetic evidence also implicates CBP/p300 as a negative regulator of cell growth, based on its interactions with adenovirus Ela, SV40 large T antigen and the tumour suppressor p53, among others. With regard to p53-CBP/p300 complex formation, functional interaction between these two important growth regulatory proteins accounts for several of the known activities of p53 (3,28,40); interestingly, CBP/p300 was shown recently to acetylate p53 and stimulate its transactivation potential (27).

It will be of interest to determine whether IRF-3 is similarly modified by CBP association. The functional consequences of IRF-3 interaction with CBP/p300 remain to be elucidated, although recent studies demonstrated that CBP/p300 also functionally interacts with STAT 1 (68) and STAT 2 (7) and may contribute to IFN α and IFN γ nuclear signalling. Recently published studies have demonstrated that synergistic activation of the IFN β promoter requires recruitment of CBP/p300 to the enhanceosome, via a new activating surface assembled from the activation domains of all the transcription factors in the enhanceosome (37,45). Alterations in any of the activation domains decreased both CBP recruitment and transcriptional synergy. By analogy, recruitment of CBP/p300 to DNA bound IRF-3 is likely required for maximal transcriptional activation. Association requires the interaction of the C-terminal domain of IRF-3 and the C-terminal interaction domain of CBP, a region previously shown to associate with the p53 tumour suppressor, whereas STAT1 and STAT2 associate with different regions of CBP (7,68).

Virus induced phosphorylation of IRF-3 also represents a signal for proteasome mediated degradation of IRF-3, since mutation of the Ser-396/Ser-398 or the use of proteasome inhibitors prevented the post infection degradation of IRF-3. Virus induced degradation of IRF-3 is reminiscent of the virus-induced turnover of another member of the IRF family - IRF-2. In response to dsRNA or viral induction, the 50 kD

IRF-2 protein is proteolytically processed into a smaller, 24-27 kDa protein (51) comprising the 160 aa DBD of IRF-2, termed TH3 (14) or In4 (65). Although TH3 has been shown to bind DNA and repress transcription more efficiently than the full length IRF-2 protein (42), its physiological role is not clear. Since the induction kinetics of TH3 are slower than that of IFN- β in response to dsRNA or viral infection (14), it has been suggested that the IRF-2 cleavage product may be a post-induction repressor of IFN- β gene expression (65).

Virus induced phosphorylation of IRF-3 at the C-terminal Ser/Thr residues and its subsequent degradation by a proteasome dependent pathway are also similar to the well studied phosphorylation and degradation of I κ B α which leads to activation of NF- κ B binding activity (reviewed in 4,6). In unstimulated cells, NF- κ B heterodimers are retained in the cytoplasm by inhibitory I κ B proteins. Upon stimulation by many activating agents, including cytokines, viruses and dsRNA, I κ B α is rapidly phosphorylated and degraded, resulting in the release and nuclear translocation of NF- κ B. The amino-terminus of I κ B α represents a signal response domain for activation of NF- κ B and substitution of alanine for either Ser-32 or Ser-36 completely abolished the signal-induced phosphorylation and degradation of I κ B α , and blocked the activation of NF- κ B. These mutations also blocked *in vitro* ubiquitination of the I κ B α protein. The amino-terminus of I κ B α is necessary for signal-induced phosphorylation and ubiquitination, but for degradation to occur, there is an absolute requirement for the C-terminal PEST domain (reviewed in 4,6).

Similarities and differences exist between the observed degradation of IRF-3 and the mechanism of I κ B α degradation. The C-terminal phosphorylation of IRF-3 as a consequence of virus infection is required for its subsequent degradation based on the deletion and point mutation analysis of the region -ISNSHPLSLTSDQ- between amino acids 395 and 407. Minimally, phosphorylation of Ser-396 and Ser-398 are required for subsequent degradation, although Ser-402, Ser-404 and Ser-405 may represent secondary phosphorylation sites.

Likewise, in the case of I κ B α , phosphorylation and Ser-32 and Ser-36 are required for inducer mediated degradation. Furthermore, the protease inhibitor calpain inhibitor I and the more specific proteasome inhibitor MG132 block IRF-3 turnover.

5 A major difference in the mechanisms of I κ B α and IRF-3 turnover lies in the nature of the inducing stimuli. Multiple inducers - cytokines such as TNF and IL-1, viruses, LPS, oxidative stress, etc (6) - all lead to the induction of I κ B α phosphorylation and degradation whereas IRF-3
10 phosphorylation appears to be induced only by virus infection and dsRNA addition; other inducers have not resulted in IRF-3 turnover.

 A significant temporal difference also exists between I κ B α phosphorylation/turnover and IRF-3
15 phosphorylation/degradation. Many activators of NF- κ B stimulate I κ B α phosphorylation within minutes and TNF induced degradation occurs within the first 15-30 minute after treatment. In the case of IRF-3, phosphorylation is not detected until 6-8 hours after infection and continues in a
20 heterogenous manner over the next 10-12 hours. Previous experiments have, however, demonstrated that Sendai virus-induced turnover of I κ B α also occurs slowly over several hours (24).

 Based on the data presented herein and by analogy
25 with the properties of other IRF family members (48), the following model is proposed to explain several observations. IRF-3 exists in a latent state in the cytoplasm of uninfected cells; the C-terminus may physically interact with the DNA binding domain in such a way as to obscure both the DBD and the
30 IAD regions of the protein; the presence of an autoinhibitory domain within the C-terminal 20aa (407-427) would explain the activating effect of this deletion, as seen previously with IRF-4 (11,19). Virus induced phosphorylation at the Ser/Thr at 396-405aa cluster leads to a conformational change in IRF-3,
35 exposing both the DBD and IAD and relieving C-terminal autoinhibition. Translocation to the nucleus, occurring via an

unidentified nuclear localization sequence or in conjunction with a transcriptional partner associating through the IAD region, leads to DNA binding at ISRE- and PRDI/PRDIII-containing promoters. Phosphorylation is also
5 necessary for IRF-3 association with the chromatin remodelling activity of CBP/p300. The presence of a NES element ultimately shuttles IRF-3 from the nucleus and terminates the initial activation of IFN responsive promoters. The phosphorylated form of IRF-3 exported from the nucleus may now be susceptible
10 to proteasome mediated degradation. This scenario shares several features with the protein synthesis independent activation of NF- κ B, and further suggests that IRF-3 may represent a component of virus- or dsRNA-inducible complexes such as DRAF (16) or VIC (10,29) that could play a primary role
15 in the induction of IFN- or IFN responsive genes.

In view of the above-mentioned properties, and in particular its ability to stimulate an immune response, IRF protein is useful as a tumour suppressor.

The invention is described in more detail in the
20 following examples.

Example 1: Plasmid constructions and Mutagenesis.

The IRF-3 expression plasmid was prepared by cloning the *EcoRI-XhoI* fragment containing the IRF-3 cDNA from the pSKIRF-3 plasmid downstream of the CMV promoter of CMVBL
25 vector. CMVt-IRF-3 was constructed by cloning of IRF-3 cDNA downstream of the doxycycline-responsive promoter CMVt at the *BamHI* site of the neo CMVt BL vector (49). cDNAs encoding IRF-3 carboxyl terminal deletion mutations were generated by 28 cycles of PCR amplification with Vent DNA polymerase. DNA
30 oligonucleotide primers were synthesized using an Applied Biosystems DNA/RNA synthesizer. The amino-terminal primer was synthesized with an *EcoRI* restriction enzyme site and the carboxyl-terminal primers were synthesized with *XbaI* restriction enzyme sites at their ends. The PCR products were
35 purified by phenol/chloroform extraction and ethanol precipitation, digested with *EcoRI* and *XbaI*, and inserted into *EcoRI/XbaI* sites of CMVBL vector.

The point mutations of IRF-3 were generated by overlap PCR mutagenesis using Vent DNA polymerase. Mutations were confirmed by sequencing.

The N-terminal deletion mutations (Δ N, Δ N2A, Δ N3A and Δ N5A) of IRF-3 were generated by digestion of the related IRF-3/CMVBL plasmid with *Bam*HI (filled in with Klenow enzyme), partial digestion with *Sca*I, and re-ligation. GFP-IRF-3 expression plasmids were generated by cloning of cDNAs encoding wild type or mutated forms of IRF-3 into the downstream of EGFP in the pEGFP-C1 vector (Clontech). For construction of plasmids encoding myc-tagged CBP truncated proteins, the cDNAs coding for CBP were generated from the pRC-RSV/mCBP plasmid (provided by Dr. Dimitris Thanos) by PCR amplification. The cDNA fragments were cloned in the downstream of myc-tag in 5' myc-PCDNA3 vector (provided by Dr. Stephane Richard).

For the construction of pFlag-IRF-7, the IRF-7 cDNA was created by PCR and the resulting product was cloned into pFlag CMV-2 vector. To generate the IRF-7(aa1-246)-IRF-3(5D)(aa132-427) chimera, the cDNA encoding IRF-3 (5D) (aa132-427) was cut out from IRF-3 (5D)/CMVBL plasmid with *Sca*I and *Not*I (blunted with Klenow enzyme) and was cloned into pFlag-IRF-7 (digested with *Sma*I, which removed the C-terminal region of IRF-7 from 247-503) in frame with the IRF-7 N-terminal amino acid sequence (1-246). The point mutations of IRF-7 (D477-D479) were generated by overlap PCR mutagenesis essentially as described above for IRF-3 using Vent DNA polymerase. Codon AGC encoding residues Ser 477 and Ser 479 were mutated to GAC (Asp). Mutations were confirmed by sequencing.

Example 2: Generation of IRF-3 cell lines.

Plasmid CMVt-rtTA (49) was introduced into 293 cells by a calcium phosphate-based method. Cells were selected beginning at 48h after transfection for about one week in α MEM media (GIBCO-BRL) containing 10% heat-inactivated calf serum, glutamine, antibiotics and 2.5 ng/ μ l puromycin (Sigma). Resistant cells carrying the CMVt-rtTA plasmid (rtTA-293 cells) were then transfected with the CMVt-IRF-3 plasmid. Cells were selected beginning at 48h for a period of approximately 2 weeks

in α MEM containing 10% heat-inactivated calf serum, glutamine, antibiotics, 2.5 ng/ μ l puromycin and 400 μ g/ml G418 (Life Technologies, Inc.).

Example 3: Cell culture and transfections.

- 5 All transfections for CAT assay were carried out in human embryonic kidney 293 cells or NIH3T3 cells grown in α MEM (293) or Dulbecco's MEM (NIH3T3) media (GIBCO-BRL) supplemented with 10% calf serum, glutamine and antibiotics. Subconfluent cells were transfected with 5 μ g of CsCl purified
- 10 chloramphenicol acetyltransferase (CAT) reporter and expression plasmids by calcium phosphate coprecipitation method (293 cells) or lipofectamine (NIH3T3 cells). The reporter plasmids were the SV β CAT and ISG15 CAT reporter genes (56); also the transfection procedures were previously described (41,56). For
- 15 individual transfections, 100 μ g (SV β CAT) or 10 μ g (ISG15 CAT) of total protein extract was assayed for 1-2h at 37°C. The CAT activity was normalized with β -Gal assay. All transfections were performed 3-6 times.

Example 4: Western blot analysis of IRF-3 modification and

20 degradation.

- To characterize the posttranslational regulation of IRF-3 protein, stable or transiently transfected IRF-3 expressing cells were infected with Sendai Virus (80 HAU/ml) or treated with 5 ng/ml TNF- α , either with or without addition of
- 25 50 μ g/ml cycloheximide. In some experiments, cells were treated with either 100 μ M calpain inhibitor I (ICN), 40 μ M MG132 proteasome inhibitor, or an equivalent volume of their respective solvent (ethanol) as control. Cells were washed with phosphate-buffered saline and lysed in 10 mM Tris-Cl pH
- 30 8.0, 200 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol (DTT), 0.5% Nonidet P-40 (NP-40), 0.5 mM phenylmethanesulfonyl fluoride (PMSF), 5 μ g/ml leupeptin, 5 μ g/ml pepstatin, and 5 μ g/ml aprotinin. Equivalent amounts of whole cell extract (20 μ g) were subject to SDS-polyacrylamide gel electrophoresis
- 35 (SDS-PAGE) in a 10% polyacrylamide gel. After electrophoresis, the proteins were transferred to Hybond transfer membrane (Amersham) in a buffer containing 30 mM Tris, 200 mM glycine

and 20% methanol for 1h. The membrane was blocked by incubation in phosphate-buffered saline (PBS) containing 5% dried milk for 1h and then probed with IRF-3 antibody in 5% milk/PBS, at a dilution of 1:3000. These incubations were done at 4°C overnight or at RT for 1-3h. After four 10 minute washes with PBS, membranes were reacted with a peroxidase-conjugated secondary goat anti-rabbit antibody (Amersham) at a dilution of 1:2500. The reaction was then visualized with the enhanced chemiluminescence detection system (ECL) as recommended by the manufacturer (Amersham Corp.).

Example 5: Phosphatase treatment.

Twenty to sixty μ g of whole cell extract were treated with 0.3 units of potato acidic phosphatase (Sigma) in a final volume of 30 μ l PIPES buffer (10 mM PIPES pH 6.0, 0.5 mM PMSF, 5 μ g/ml aprotinin, 1 μ g/ml leupeptin, and 1 μ g/ml pepstatin) or 5 units of calf intestine alkaline phosphatase (Pharmacia) in 30 μ l CIP buffer. The phosphatase inhibitor mix contained 10 mM NaF, 1.5 mM Na_2MoO_4 , 1 mM β -glycerophosphate, 0.4 mM Na_3VO_4 and 0.1 μ g/ml okadaic acid.

Example 6: Subcellular localization of GFP-IRF-3 proteins.

To analyse the subcellular localization of wild type and mutated forms of IRF-3 proteins in uninfected and virus infected cells, the GFP-IRF-3 expression plasmids (5 μ g) were transiently transfected into COS-7 cells by the calcium phosphate coprecipitation method. For virus infection, transfected cells were infected with Sendai virus (80 hemagglutinating units per mL for 2h) at 24h post transfection. GFP fluorescence was analyzed in living cells with a Leica fluorescence microscope using a 40x objective.

Example 7: Electromobility Shift Assay.

Nuclear extracts were prepared from 293 cells at different times after infection with Sendai virus (80HAU/mL). In some experiments, extracts were prepared from cells transfected with different IRF-3 expression plasmids, as indicated in individual experiments. Cells were washed in Buffer A [10 mM HEPES, pH 7.9; 1.5 mM MgCl_2 ; 10 mM KCl; 0.5 mM dithiothreitol (DTT); and 0.5 mM phenylmethylsulfonyl fluoride

- (PMSF)] and were resuspended in Buffer A containing 0.1% NP-40. Cells were then chilled on ice for 10 minutes before centrifugation at 10,000 g. Pellets were then resuspended in Buffer B (20mM HEPES, pH 7.9; 25% glycerol; 0.42 M NaCl; 1.5 mM MgCl₂; 0.2 mM EDTA; 0.5 mM DTT; 0.5 mM PMSF; 5 µg/ml leupeptin; 5 µg/ml pepstatin; 0.5 mM spermidine; 0.15 mM spermine; and 5 µg/ml aprotinin). Samples were incubated on ice for 15 minutes before being centrifuged at 10,000 g. Nuclear extract supernatants were diluted with Buffer C (20 mM HEPES, pH 7.9; 20% glycerol; 0.2 mM EDTA; 50 mM KCl; 0.5 mM DTT; and 0.5 mM PMSF). Nuclear extracts were subjected to EMSA by using a 32P-labelled probe corresponding to the PRDIII region of the IFN-β promoter (5'-GGAAACTGAAAGGG-3') or the ISRE region of the ISG-15 promoter (5'-GATCGGGAAAGGGAAACCGAAACTGAAGCC-3').
- The resulting protein-DNA complexes were resolved by 5% polyacrylamide gel and exposed to X-ray film. To demonstrate the specificity of protein-DNA complex formation, 125-fold molar excess of unlabelled oligonucleotide was added to the nuclear extract before adding labelled probe.
- Example 8: Immunoprecipitation and Western analysis of CBP associated proteins.

Whole cell extract (300 µg) were prepared from either transfected or untransfected cells and precleared with 5 µl of preimmune rabbit serum and 20 µl of protein A-Sepharose beads (Pharmacia) for 1 hour at 4°C. The extract was incubated with 10 µl of anti-CBP antibody A-22 (Santa Cruz) or 2 µl anti-myc antibody 9E10 (21) and 30 µl of protein A-Sepharose beads for 2-3 hours at 4°C. Precipitates were washed 5 times with lysis buffer, eluted by boiling the beads 3 minutes in 1x SDS sample buffer. Eluted proteins were separated by SDS PAGE, transferred to Hybond transfer membrane. Membranes were incubated with anti-IRF-3 (1:3000) or anti-myc antibody 9E10 (1:1000). Immunocomplexes were detected by using a chemiluminescence-based system.

- The results of the above examples are summarized below.

Virus induced phosphorylation of IRF-3 protein.

IRF-3 is expressed constitutively in various cells and its expression is not enhanced by viral infection or by IFN treatment. To investigate whether the IRF-3 protein is regulated by post-translational modification after virus infection, 293 cells were transiently transfected with an IRF-3 expression plasmid and subsequently infected with Sendai virus 24h later. In cells transfected with CMVBL vector alone, endogenous IRF-3 protein was easily detected using a polyclonal IRF-3 antibody and in cells transfected with the IRF-3 expression plasmid, IRF-3 protein levels were significantly increased (Fig.1, lanes 1 and 3). Interestingly, Sendai virus infection resulted in two alterations in the expression of IRF-3: 1) an overall decrease in the amount of IRF-3 in transfected and control cells (Fig. 1, lanes 2 and 4) and the generation of a more slowly migrating form of IRF-3 (Fig. 1, compare lanes 1 and 2). In all experiments, the turnover of IRF-3 after virus infection was more pronounced with the endogenous protein than with the transfected proteins (see Fig.1, as well as others). Because the transfected proteins were driven by the CMV promoter, ongoing synthesis of transfected IRF-3 may partially obscure the turnover of IRF-3.

The kinetics of virus-induced modification of IRF-3 were characterized in a 293 cell line that expressed IRF-3 inducibly under the control of the tetracycline responsive promoter CMVt (25,26). Infection of this cell line (designated rtTA-IRF-3) with Sendai virus resulted in a decrease in the amount of IRF-3 between 12 and 24h after infection (Fig. 2A). Two forms of IRF-3 protein (designated I and II) were detected in uninfected cells (Fig. 2A, lane 1) and following virus infection, a third slowly migrating form of IRF-3 was also detected (Fig.2A, lanes 4-7). To determine whether the slowest form of IRF-3 was due to virus-induced phosphorylation (P-IRF-3), the different forms of IRF-3 were subjected to treatment in vitro with potato acidic phosphatase (PPA) or calf intestine alkaline phosphatase (CIP) and/or phosphatase inhibitors (Fig. 2B). These treatments did not affect the

mobilities of forms I and II in uninfected cells (Fig. 2B, lanes 1-3). However, in rtTA-IRF-3 expressing 293 cells infected with Sendai virus for 12h, an additional slowly migrating, presumably phosphorylated form of IRF-3 was also detected (Fig. 2B, lane 6); this form of IRF-3 completely disappeared following CIP or PPA treatment (Fig. 2B, lanes 6 and 7) but was maintained in the presence of CIP/PPA when phosphatase inhibitors were also added to the reaction (Fig. 2B, lanes 5 and 8).

10 Mapping the IRF-3 phosphorylation sites.

A series of deletions of IRF-3 were generated to identify the virus-induced phosphorylation site(s) of IRF-3 (Fig. 3A). 293 cells were transiently transfected with IRF-3 deletion mutants and the virus mediated phosphorylation was measured by immunoblotting (Fig. 3B). The results indicated that a virus-induced phosphorylation of IRF-3 occurs at the C-terminal end of IRF-3 since the mutations that contained only the N-terminal part of IRF-3 protein (133, 240, 328, 357 or 394aa) were not phosphorylated (Fig. 3B). Full length and 407aa forms of IRF-3 were phosphorylated as a consequence of virus infection (Fig. 3B, lanes 1-4). C-terminal truncation of IRF-3 to a protein of 394 or 357aa removed the site(s) of inducible phosphorylation (Fig. 3B, lanes 5-8), although the shortened versions of forms I and II were still observed. Also in the IRF-3 Δ 9-133 mutation (Δ N) which had the DNA binding, N-terminal amino acids (aa9 to aa133) removed, both virus induced phosphorylation of IRF-3 and the differential migration of the shortened forms I and II were easily detected (Fig. 3B, lanes 9 and 10). Degradation of the endogenous forms of IRF-3 by virus infection was also detected in this experiment (compare Fig. 3B, lanes 7 and 9 with lanes 8 and 10).

Thus, by deletion analysis, a phosphorylation domain of IRF-3 protein was localized to the region -ISNSHPLSLTSDQ- between amino acids 395 and 407. Point mutations in the several putative Ser and Thr phosphorylation residues within this region were generated in the full length protein and the Δ 9-133 (Δ N) protein (Fig. 4A). In the IRF-3 cDNA encoding

these proteins, the Ser-396/Ser398/Ser-402/Thr-404/Ser-405 residues were replaced by alanine (5A), as were the three residues Ser-402/Thr-404/Ser-405 (3A) and the two residues Ser-396/Ser-398 (2A). Transfection of these plasmids into 293 cells and subsequent virus infection revealed that full length wild type IRF-3 was phosphorylated (Fig. 4B, lanes 4 and 8), whereas the IRF-3 proteins containing 2A and 5A mutations were no longer phosphorylated in virus infected cells (Fig. 4B, lanes 6 and 10). Interestingly, IRF-3-3A was also very weakly phosphorylated as a consequence of virus infection, thus implicating Ser-402/Thr-404/Ser-405 as potential secondary sites of phosphorylation. Using the ΔN IRF-3 protein and the relevant point mutations, phosphorylation was detected with ΔN (Fig. 4B, lane 12) but not with ΔN -2A and ΔN -5A (Fig. 4B, lanes 14 and 18); likewise, ΔN -3A displayed very weak phosphorylation (Fig. 4B, lane 16).

These experiments thus implicate Ser-396 and Ser-398 as critical sites of virus-induced phosphorylation of IRF-3; however, Ser-402/Thr-404/Ser-405 residues also contribute to the observed phosphorylation, since the migration of phosphorylated ΔN -3A is significantly faster than ΔN and the phosphorylation level is decreased (Fig. 4B, lanes 12 and 16). Another study suggested the involvement of the Ser residues at aa385 and 386 as potential phosphoacceptor sites (67).

However, in studies with the S385A/S386A mutation, no evidence was found for inducible phosphorylation at these sites.

Nevertheless, since these sites represent consensus sites for CKI and CKII, constitutive phosphorylation is a possibility.

IRF-3 phosphorylation induces cytoplasmic to nuclear

translocation of IRF-3.

Initial studies indicated that IRF-3 was localized in the cytoplasm of uninfected cells (67); to investigate the role of phosphorylation on IRF-3 localization, wild type and point mutated forms of IRF-3 were linked to green fluorescent protein (GFP), transfected into COS-7 cells and examined for Sendai virus induced changes in subcellular localization (Fig. 5). In uninfected cells, GFP-IRF-3 localized exclusively to the

cytoplasm; Sendai virus infection resulted in translocation of IRF-3 to the nucleus within 8h in 90-95% of the cells (Fig. 5A and B). Mutation of the Ser/Thr cluster in GFP-IRF-3(5A) completely abrogated virus-induced cytoplasmic to nuclear translocation (Fig. 5, C and D). Interestingly, the substitution of the Ser/Thr cluster with the phosphomimetic Asp in GFP-IRF-3(5D) likewise altered subcellular localization. IRF-3(5D) localized both to the nucleus and cytoplasm in uninfected cells (Fig. 5E), while virus infection resulted in an intense nuclear pattern of IRF-3(5D) fluorescence (Fig. 5F). Point mutation of a putative nuclear export signal in IRF-3, the L145A/L146A modification - termed IRF-3(NES) - also changed subcellular localization of IRF-3. In uninfected cells, GFP-IRF-3(NES) was localized to the nucleus and cytoplasm, with a homogeneous, extra-nucleolar pattern of nuclear staining. After virus infection, GFP-IRF-3(NES) localized to the nucleus with an intense speckled pattern of nuclear fluorescence in greater than 95% of the cells, suggesting that IRF-3(NES) may be trapped in the nucleus associated with the nuclear pore complex.

Transactivation of PRDI/PRDIII and ISRE promoters by IRF-3.

Next, the capacity of IRF-3 to regulate gene expression was analysed by transient transfection in human 293 and murine NIH3T3 cells using the IFN β and ISG-15 promoters in reporter gene assays. Expression of NF- κ B RelA(p65), IRF-1 and IRF-3 alone minimally induced IFN β promoter activity between 3 to 4 fold (Fig. 6A and B), as shown previously (24,56,61). Introduction of the C-terminal point mutants - IRF-3(2A), IRF-3(3A) IRF-3(5A) - reduced the low transactivation capacity of IRF-3 to control levels (Fig. 6A). Interestingly, deletion of the C-terminal 20aa of IRF-3 to IRF-3(407) stimulated IFN β activity about 6 fold, indicative of the removal of an inhibitory domain in IRF-3. However, further deletion to 394, 357 or 240 abrogated transactivation potential (Fig. 6A). Mutation of the NES element was not sufficient to stimulate IFN β activity. Strikingly, the substitution of the Ser/Thr cluster at aa397-405 in IRF-3 with the phosphomimetic Asp

generated a very strong, constitutive transactivator protein that alone stimulated the IFN β promoter 90 fold.

As shown previously, high level induction of the IFN β promoter requires synergistic activation by NF- κ B and IRF proteins (24,61). To analyse the properties of IRF-3 in synergistic activation of the IFN β promoter, co-expression studies were performed using RelA(p65) expression plasmid and different wild type and mutant forms of IRF-3 (Fig. 6B). Co-expression of RelA and IRF-1 or RelA and IRF-3 stimulated IFN β -CAT activity by 20-25 fold. IRF-3(407) and RelA(p65) stimulated IFN β activity about 40 fold, supporting the idea of the removal of an inhibitory domain in IRF-3, whereas both the IRF-3(394) and the IRF-3(NES) failed to synergise with RelA in the activation of the IFN β promoter. RelA and IRF-3(NES) produced a relatively weak 8 fold induction of IFN β expression, indicating that nuclear localization is not sufficient for IRF-3 activation. The combination of RelA and IRF-3(5D) produced an 80 fold stimulation of IFN β promoter activity (Fig. 6B); together with the above data, IRF-3(5D) alone appears to be capable of full stimulation of the IFN β promoter and further synergy with RelA is not observed (compare Fig. 6A and B). Surprisingly, IRF-3(5A) and RelA produced a 30 fold stimulation, suggesting that 5A can still synergise with RelA, despite mutation of the Ser/Thr cluster.

The transactivation potential of IRF-3 was also analysed using the ISG-15 promoter, an ISRE containing regulatory element (Fig. 6C). As shown previously (2), and above for the IFN β promoter, IRF-3 alone weakly activated the ISG-15 promoter; in the context of this regulatory element, IRF-3 was weaker than IRF-1, which produced a 9 fold stimulation. Again deletion of the C-terminal 20aa of IRF-3 generated a protein that stimulated gene expression; with the ISG-15 promoter, a 12 fold induction was observed; IRF-3(394) and IRF-3(357) did not stimulate gene expression but rather slightly repressed ISG-15. Again remarkably, IRF-3(5D) produced a 50 fold induction of the ISG-15 promoter (Fig. 6C), thus demonstrating that substitution of the Ser/Thr sites with

the phosphomimetic Asp generated a constitutively active form of IRF-3 that functioned as a very strong activator of promoters containing PRDI/PRDIII or ISRE regulatory elements.

Activation of RANTES Transcription by IRF-3 and Virus

5 Chemokine expression is demonstrated in Figure 7, the chemokine being RANTES (Regulated on Activation Normal T-cell Expressed and Secreted) protein. IRF-3-inducible cells were used to determine whether other cytokine-chemokine genes may be regulated by IRF-3; an (Rnase Protection Analysis (RPA) with
10 multiple human cytokine-chemokine probes (PharMingen) was used to examine RNA derived from rtTA-IRF-3 or rtTA-IRF-3(5D) cells. Strikingly, the RANTES gene was highly expressed in the IRF-3(5D)-inducible cells, as well as in virus-infected cells (Fig. 7A, lanes 3, 5, and 7) but not in uninfected rtTA- or wt IRF-3-
15 expressing cells (Fig. 7A, lanes 1 and 4). Since IRF-3(5D) was a strong transactivator of the IFN- β promoter in transient transfection assays, the possibility of an autoregulatory effect of IFN- α/β expression on transcription of RANTES promoter via JAK-STAT activation was considered. Activation of
20 RANTES did not occur secondary to the production of IFN- α/β , since RANTES mRNA was not detected in control rtTA-expressing cells treated directly with IFN- α/β (Fig. 7A, lane 2); furthermore, addition of neutralizing antibody directed against type I IFN did not block the stimulation of RANTES gene
25 expression by IRF-3(5D) (Fig. 7A, lane 8). Other experiments also demonstrated that IRF-3 itself was not activated by IFN treatment (13a). Inducible expression of RANTES in cells stably expressing a dominant-negative form of IRF-3 which lacks the N-terminal amino acids 9 to 133 and does not bind to DNA
30 was also examined. As shown in Fig. 7B, RANTES gene transcription was induced by Sendai virus in control (rtTA) cells (Fig. 7B) but not in IRF-3 (Δ N)-expressing cells (Fig. 7B). This experiment indicates that a non-DNA binding, dominant-negative mutant of IRF-3 is able to block completely
35 virus-induced activation of RANTES transcription.

The kinetics of IRF-3 transgene induction and RANTES mRNA expression were characterized at various times following

Dox induction. IRF-3(5D) was detected at 8 to 12 hours with peak levels at 24 hours following Dox addition. RANTES mRNA was first detectable at 18 hours after Dox induction with peak levels at 40 hours (Fig. 7C, lanes 5 to 10). Induction of RANTES protein expression as detected by ELISA (Fig. 7D) was first observed at 12 hours after Dox induction of IRF-3, in good agreement with the mRNA levels, and accumulated thereafter with a dramatic increase between 24 and 32 hours after stimulation, also in agreement with mRNA levels. The possibility that IRF-3(5D) may be directly activating another transcription factor such as NF- κ B, which in turn would stimulate RANTES transcription, was also considered. No evidence for IRF-3(5D)-mediated activation of NF- κ B DNA binding activity was observed. Similarly, IRF-3(5D) expression did not activate the human immunodeficiency virus (HIV)-long terminal repeat, a complex promoter controlled by NF- κ B and other transcription factors (data not shown).

Inhibition of IRF-3 degradation.

Another consequence of virus infection is the degradation of the IRF-3. Since phosphorylation of proteins is functionally associated with the process of protein degradation via the ubiquitin-dependent proteasome pathway (53,57,60), the effect of proteasome inhibitors on virus-induced turnover of IRF-3 was examined. In cells transfected with the Δ N and Δ N5A forms of IRF-3, virus induced degradation of full length (endogenous) forms of IRF-3 (Fig. 8A, lanes 1 and 4) and the truncated Δ N (Fig. 8B, lanes 1 and 4) was detected. Addition of the protease inhibitor calpain inhibitor I or the proteasome inhibitor MG132 blocked virus-induced IRF-3 degradation (Fig. 8A and 8B, lanes 4-6). Particularly with the Δ N protein, the accumulation of the phosphorylated form of Δ N was also detected in virus infected cells (Fig. 8B, lanes 5 and 6), suggesting that phosphorylation of IRF-3 may represent a signal for subsequent degradation by the proteasome pathway. To confirm this idea, the 5A point mutated form of IRF-3 was analysed; the IRF-3- Δ N5A protein was resistant to virus induced degradation (Fig. 8C, lanes 1 and 4); no further stabilization of

IRF-3-AN5A occurred with calpain inhibitor I or MG132 addition and no phosphorylated IRF-3 was detected (Fig. 8C, lanes 4-6). These experiments demonstrate that virus dependent phosphorylation of the C-terminal of IRF-3 represents a signal for subsequent proteasome mediated degradation.

Interaction between IRF-3 and CBP in virus infected cells.

To examine the possibility that IRF-3 associated with the co-activator CBP/p300 (Fig. 9A) following Sendai virus infection, CBP was immunoprecipitated from virus-infected cells with anti-CBP antibody; an immunoblot for IRF-3 revealed that IRF-3 was co-precipitated from virus-infected cells but not from uninfected cells (Fig. 9B, lanes 2 and 3). This interaction was observed clearly in cells co-transfected with the IRF-3 expression plasmid (Fig. 9B, lane 3) but was not seen when the immunoprecipitation was performed with pre-immune serum (Fig. 9B, lane 7). The endogenous IRF-3 also co-precipitated from virus-infected cells (Fig. 9B, lane 1). However, mutation of the Ser/Thr residues identified as the virus inducible phosphorylation sites abrogated the association of IRF-3 with CBP. In particular, IRF-3(2A) and IRF-3(5A) were detected in whole cell extract immunoblot but not in the CBP immunoprecipitate (Fig. 9B, compare lanes 4 and 6 with lanes 11 and 13). With the IRF-3(3A) mutant, interaction with CBP was still observed (Fig. 9B, lane 5). The high background in all lanes represents secondary antibody reactivity with rabbit IgG from the immunoprecipitation. Immunoblot analysis of the whole cell extracts revealed that phosphorylated IRF-3, as well as forms I and II were present in virus infected cells (Fig. 9B, lane 10) and in cells transfected with 2A, 3A and 5A the forms I and II were observed but not the phosphorylated form of IRF-3 (Fig. 9B, lanes 11-13).

CBP has several domains that bind transcription factors, designated CBP1, CBP2, and CBP3 respectively (Fig. 9A, reviewed in (28)). To determine which domain of CBP interacts with IRF-3, the three specific subdomains were myc-tagged at the 5' end by subcloning into the pCDNA3 vector (Fig. 9A). 293 cells were co-transfected with these myc-tagged CBP expression

plasmids together with the IRF-3 ΔN (Δ9-133) expression plasmid. At 24h after transfection, cells were infected with Sendai virus, co-immunoprecipitated with anti-myc antibody 16h later (21) and then immunoblotted for IRF-3. Endogenous IRF-3 and transfected IRF-3 ΔN proteins co-precipitated with CBP-3 from virus-infected cells but not from uninfected cells (Fig. 9C, lane 6). In cells co-transfected with CBP-1 and CBP-2, no endogenous or transfected ΔN IRF-3 was detected (Fig. 9C, lanes 1-4). Immunoblot analysis of the whole cell extracts revealed that all three myc-tagged CBP proteins were efficiently expressed in uninfected and virus infected cells (Fig. 9D). These results demonstrate that IRF-3 binds to the C-terminal domain of CBP in virus infected cells and interaction with CBP requires Ser-396/Ser-398 phosphorylation of IRF-3 but not at Ser-402/Thr-404/Ser-405.

Figure 11 shows the relative activity of various forms of IRF-3 and IRF-7, and binary mixtures thereof, in transactivation studies. Both the IRF-3(5D) and IRF-7(2D) mutants show increased activity relative to their corresponding wild-type proteins. There is a synergistic effect present when both proteins are present, and this effect is most pronounced in a mixture of the IRF-3(5D) and IRF-7(2D) (D477/479) mutants.

Figure 14 shows that the chimeric protein IRF-7(1-246)/IRF-3(5D)(132-427) has a markedly increased activity over the mixture of the IRF-3(5D) and IRF-7(2D) (D477/479) mutants.

A pharmaceutical composition may be prepared, with a protein of the invention as active ingredient, for the treatment of a viral infection, such as an influenza infection, a herpes infection or an HIV infection.

The pharmaceutical compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, transdermal (e.g., patch), intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal

administration or in a form suitable for administration by inhalation or insufflation.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).

For buccal administration the composition may take the form of tablets or lozenges formulated in conventional manner.

The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for

reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

The protein of the invention can also be made available using gene therapy. The DNA encoding the protein can be introduced to cells of an organism at a target site, for example, by a viral vector, by electroporation, by co-transfection with a selectable marker, or by DNA vaccine.

REFERENCES

1. Arany, Z., Sellers, W.R., Livingston, D.M. and Eckner, R. 1994. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators. Cell 77:799-800.
2. Au, W.-C., Moore, P.A., Lowther, W., Juang, Y.-T. and Pitha, P.M. 1995. Identification of a member of the interferon regulatory factor family that binds to the interferon-stimulated response element and activates expression

of interferon-induced genes. Proc.Natl.Acad.Sci.USA
92:11657-11661.

3. Avantaggiati, M.L., Ogryzko, V., Gardner, K., Giordano, A.,
Levine, A.S. and Kelly, K. 1997. Recruitment of p300/CBP in
5 p53-dependent signal pathways. Cell 89:1175-1184.

4. Baldwin, A.S.Jr. 1996. The NF- κ B and I κ B proteins: new
discoveries and insights. Annu.Rev.Immunol. 14:649-681.

5. Bannister, A.J. and Kouzarides, T. 1996. The CBP
coactivator is a histone acetyltransferase. Nature
10 384:641-643.

6. Beauparlant, P. and Hiscott, J. 1996. Biological and
biochemical inhibitors of the NF- κ B/Rel proteins and cytokine
synthesis. CytGrowthFactRev 7:175-190.

7. Bhattacharya, S., Eckner, R., Grossman, S., Oldread, E.,
15 Arany, Z., D'Andrea, A. and Livingston, D.M. 1996.
Cooperation of Stat2 and p300/CBP by interferon- α . Nature
383:344-347.

8. Bluyssen, H.A.R., Durbin, J.E. and Levy, D.E. 1996.
ISGF3 γ p48, a specificity switch for interferon activated
20 transcription factors. CytGrowthFactRev 7:11-17.

9. Bovolenta, C., Driggers, P.H., Marks, M.S., Medin, J.A.,
Politis, A.D., Vogel, S.N., Levy, D.E., Sakaguchi, K., Appella,
E., Coligan, J.E. and Ozato, K. 1994. Molecular interactions
between interferon consensus sequence binding protein and
25 members of the interferon regulatory factor family.
Proc.Natl.Acad.Sci.USA 91:5046-5050.

10. Bragança, J., Génin, P., Bandu, M.-T., Darracq, N., Vignal,
M., Cassé, C., Doly, J. and Civas, A. 1997. Synergism between
multiple virus-induced-factor-binding elements involved in the
30 differential expression of IFN-A genes. J.Biol.Chem. 272:
22154-22162.

11. Brass, A.L., Kehrl, E., Eisenbeis, C.F., Storb, U. and
Singh, H. 1996. Pip, a lymphoid-restricted IRF, contains a
regulatory domain that is important for autoinhibition and
35 ternary complex formation with the Ets factor PU.1. Genes Dev.
10:2335-2347.

12. Chen, H., Lin, R.J., Schiltz, R.L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M.L., Nakatani, Y. and Evans, R.M. 1997. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. *Cell* 90:569-580.
13. Chrivia, J.C., Kwok, R.P.S., Lamb, N., Hagiwara, M., Montminy, M.R. and Goodman, R.H. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. *Nature* 365:855-859.
14. Cohen, L. and Hiscott, J. 1992. Characterization of TH3, an induction specific protein interacting with the interferon- β promoter. *Virology* 191:589-599.
15. Crepieux, P., Coll, J. and Stehelin, D. 1994. The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. *Crit Rev Oncogen* 5:615-638.
16. Daly, C. and Reich, N.C. 1993. Double-stranded RNA activates novel factors that bind to the interferon stimulated response element. *Mol. Cell. Biol.* 13:3756-3764.
17. Darnell Jr., J.E., Kerr, I.M. and Stark, G.R. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 264:1415-1421.
18. Driggers, P.H., Ennist, D.L., Gleason, S.L., Mak, W.-H., Marks, M.S., Levi, B.-Z., Flanagan, J.R., Appella, E. and Ozato, K. 1990. An interferon γ -regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. *Proc. Natl. Acad. Sci. USA* 87:3743-3747.
19. Eisenbeis, C.F., Singh, H. and Storb, U. 1995. Pip, a novel IRF family member, is a lymphoid-specific, PU.1-dependent transcriptional activator. *Genes Dev.* 9:1377-1387.
20. Escalante, C.R., Yie, J., Thanos, D. and Aggarwal, A.K. 1998. Structure of IRF-1 with bound DNA reveals determinants of interferon regulation. *Nature* 391:103-106.
21. Evan, G.I. and Bishop, J.M. 1985. Isolation of monoclonal antibodies specific for the human c-myc proto-oncogene product. *Mol. Cell. Biol.* 4:2843-2850.

22. Fujita, T., Kimura, Y., Miyamoto, M., Barsoumian, E.L. and Taniguchi, T. 1989. Induction of endogenous IFN- α and IFN- β genes by a regulatory transcription factor IRF-1. *Nature* 337:270-272.
- 5 23. Fujita, T., Sakakibara, J., Sudo, Y., Miyamoto, M., Kimura, Y. and Taniguchi, T. 1988. Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN- β gene regulatory elements. *EMBO J.* 7:3397-3405.
24. Garoufalidis, E., Kwan, I., Lin, R., Mustafa, A., Pepin, N.,
10 Roulston, A., Lacoste, J. and Hiscott, J. 1994. Viral induction of the human interferon β promoter: modulation of transcription by NF- κ B/rel proteins and interferon regulatory factors. *J.Virol.* 68:4707-4715.
25. Gossen, M. and Bujard, H. 1992. Tight control of gene
15 expression in mammalian cells by tetracycline-responsive promoters. *Proc.Natl.Acad.Sci.USA* 89:5547-5551.
26. Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W. and Bujard, H. 1995. Transcriptional activation by tetracyclines in mammalian cells. *Science* 268:1766-1769.
- 20 27. Gu, W. and Roeder, R.G. 1997. Activation of p53 sequence-specific DNA binding by acetylation of p53 C-terminal domain. *Cell* 90:595-606.
28. Gu, W., Shi, X.L. and Roeder, R.G. 1997. Synergistic activation of transcription by CBP and p53. *Nature*
25 387:819-823.
29. Génin, P., Bragança, J., Darracq, N., Doly, J. and Civas, A. 1995. A novel PRDI and TG binding activity involved in virus-induced transcription of IFN-A genes. *NuclAcidRes* 23:5055-5063.
- 30 30. Harada, H., Fujita, T., Miyamoto, M., Kimura, Y., Maruyama, M., Furia, A., Miyata, T. and Taniguchi, T. 1989. Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. *Cell* 58:729-739.
- 35 31. Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Kimura, T., Kitagawa, M., Yokochi, T., Tan, R.S.-P., Takasugi, T., Kadokawa, Y., Schindler, C., Schreiber, R.D., Noguchi, S.

- and Taniguchi, T. 1996. Regulation of IFN- α/β genes: evidence for a dual function of the transcription factor complex ISGF3 in the production and action of IFN- α/β . *GenestoCells* 1:995-1005.
- 5 32. Harada, H., Willison, K., Sakakibara, J., Miyamoto, M., Fujita, T. and Taniguchi, T. 1990. Absence of type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. *Cell* 63:903-913.
- 10 33. Hiscott, J., Nguyen, H. and Lin, R. 1995. Molecular mechanisms of interferon β gene induction. *SeminVirol* 6:161-173.
34. Holtschke, T., Löhler, J., Kanno, Y., Fehr, T., Giese, N., Rosenbauer, F., Lou, J., Knobloch, K.-P., Gabriele, L.,
- 15 Waring, J.F., Bachmann, M.F., Zingernagel, R.M., Morse III, H.C., Ozato, K. and Horak, I. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. *Cell* 87:307-317.
35. Ihle, J.N. 1996. STATs: signal transducers and
- 20 activators of transcription. *Cell* 84:331-334.
36. Kawakami, T., Matsumoto, M., Sato, M., Harada, H., Taniguchi, T. and Kitigawa, M. 1995. Possible involvement of the transcription factor ISGF3 γ in virus-induced expression of the IFN- β gene. *FEBS Lett.* 358:225-229.
- 25 37. Kim, T.K. and Maniatis, T. 1998. The mechanism of transcriptional synergy of an in vitro assembled interferon β enhanceosome. *Mol.Cell* 1:119-129.
38. Kimura, T., Kadokawa, Y., Harada, H., Matsumoto, M., Sato, M., Kashiwazaki, Y., Tarutani, M., Tan, R.S-P., Takasugi, T.,
- 30 Matsuyama, T., Mak, T.M., Noguchi, S. and Taniguchi, T. 1996. Essential and non-redundant roles of p48 (ISGF3 γ) and IRF-1 in both type I and type II interferon responses, as revealed by gene targeting studies. *GenestoCells* 1:115-124.
39. Levy, D.E. 1995. Interferon induction of gene expression
- 35 through the Jak-Stat pathway. *SeminVirol* 6:181-190.

40. Lill, N.L., Grossman, S.R., Ginsberg, D., DeCaprio, J. and Livingston, D.M. 1997. Binding and modulation of p53 by p300/CBP coactivators. *Nature* 387:823-827.
41. Lin, R., Beauparlant, P., Makris, C., Meloche, S. and Hiscott, J. 1996. Phosphorylation of I κ B α in the C-terminal PEST domain by casein kinase II affects intrinsic protein stability. *Mol.Cell.Biol.* 16:1401-1409.
42. Lin, R., Mustafa, A., Nguyen, H. and Hiscott, J. 1994. Mutational analysis of interferon (IFN) regulatory factors 1 and 2: Effects on the induction of IFN- β gene expression. *J.Biol.Chem.* 269:17542-17549.
43. Matsuyama, T., Grossman, A., Mittrfcker, H.-W., Siderovski, D.P., Kiefer, F., Kawakami, T., Richardson, C.D., Taniguchi, T., Yoshinaga, S.K. and Mak, T.W. 1995. Molecular cloning of LSIRF, a lymphoid-specific member of the interferon regulatory factor family that binds the interferon-stimulated response element (ISRE). *NuclAcidRes* 23:2127-2136.
44. Matsuyama, T., Kimura, T., Kitagawa, M., Watanabe, N., Kundig, T., Amakawa, R., Kishihara, K., Wakeham, A., Potter, J., Furlonger, C., Narendran, A., Suzuki, H., Ohashi, P., Paige, C., Taniguchi, T. and Mak, T. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN induction and aberrant lymphocyte development. *Cell* 75:83-97.
45. Merika, M., Williams, A., Chen, G., Collins, T. and Thanos, D. 1998. Recruitment of CBP/p300 by the IFN β enhanceosome is required for synergistic activation of transcription. *Mol.Cell* 1:277-287.
46. Mittrücker, H.-W., Matsuyama, T., Grossman, A., Kündig, T.M., Potter, J., Shahinian, A., Wakeham, A., Patterson, B., Ohashi, P.S. and Mak, T.W. 1997. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. *Science* 275:540-543.
47. Miyamoto, M., Fujita, T., Kimura, Y., Maruyama, M., Harada, H., Sudo, Y., Miyata, T. and Taniguchi, T. 1988. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to the IFN- β gene regulatory elements. *Cell* 54:903-913.

48. Nguyen, H., Hiscott, J. and Pitha, P.M. 1997. The growing family of IRF transcription factors. CytGrowthFactRev 8:in press.
49. Nguyen, H., Lin, R. and Hiscott, J. 1997. Activation of
5 multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. Oncogene 15:1425-1435.
50. Ogryzko, V.V., Schiltz, R.L., Russanova, V., Howard, B.H. and Nakatani, Y. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87:953-959.
- 10 51. Palombella, V. and Maniatis, T. 1992. Inducible processing of interferon regulatory factor-2. Mol.Cell.Biol. 12:3325-3336.
52. Pitha, P.M. and Au, W.-C. 1995. Induction of interferon α gene expression. SeminVirol 6:151-159.
- 15 53. Read, M.A., Neish, A.S., Luscinskas, F.W., Palombella, V.J., Maniatis, T. and Collins, T. 1995. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 2:493-506.
54. Reis, L.F.L., Harada, H., Wolchok, J.D., Taniguchi, T. and
20 Vilcek, J. 1992. Critical role of a common transcription factor, IRF-1, in the regulation of IFN- β and IFN-inducible genes. EMBO J. 11:185-193.
55. Russo, J.J., Bohenzky, R.A., Chien, M.-C., Chen, J., Yan, M., Maddalena, D., Parry, J.P., Peruzzi, D., Edelman, I.S.,
25 Chang, Y. and Moore, P. 1996. Nucleotide sequence of the kaposi sarcoma-associated herpesvirus (HHV8). Proc.Natl.Acad.Sci.USA 93:14862-14867.
56. Schafer, S., Lin, R., Moore, P., Hiscott, J. and Pitha, P.M. 1998. Regulation of type 1 interferon gene expression by
30 interferon regulatory factor 3. J.Biol.Chem. 273:2714-2720.
57. Scherer, D.C., Brockman, J.A., Chen, Z., Maniatis, T. and Ballard, D.W. 1995. Signal-induced degradation of I κ B α requires site-specific ubiquitination. Proc.Natl.Acad.Sci.USA 92:11259-11263.
- 35 58. Schindler, C. and Darnell Jr., J.E. 1995. Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Ann.Rev.Biochem. 64:621-651.

59. Sharf, R., Meraro, D., Azriel, A., Thornton, A.M., Ozato, K., Petricoin, E.F., Larner, A.C., Schaper, F., Hauser, H. and Levi, B.-Z. 1997. Phosphorylation events modulate the ability of interferon consensus sequence binding protein to interact with interferon regulatory factors and to bind DNA. *J.Biol.Chem.* 272:9785-9792.
60. Thanos, D. and Maniatis, T. 1995. NF- κ B: a lesson in family values. *Cell* 80:529-532.
61. Thanos, D. and Maniatis, T. 1995. Identification of the rel family members required for virus induction of the human β interferon gene. *MolCellBiol* 15:152-164.
62. Veals, S.A., Schindler, C., Leonard, D., Fu, X.-Y., Aebersold, R., Darnell Jr., J.E. and Levy, D.E. 1992. Subunit of an α -interferon-responsive transcription factor is related to interferon regulatory factor and myb families of DNA-binding proteins. *MolCellBiol* 12:3315-3324.
63. Vilcek, J. and Sen, G. Interferons and other cytokines. In: *Virology*, edited by Fields, B., Knipe, D.M. and Howley, P.M. Philadelphia: Lippincott-Raven, 1996, p. 375-399.
64. Weisz, A., Marx, P., Sharf, R., Appella, E., Driggers, P.H., Ozato, K. and Levi, B.-Z. 1992. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. *J.Biol.Chem.* 267:25589-25596.
65. Whiteside, S.T., King, P. and Goodbourn, S. 1994. A truncated form of the IRF-2 transcription factor has the properties of a postinduction repressor of interferon- β gene expression. *J.Biol.Chem.* 269:27059-27065.
66. Yamagata, T., Nishida, J., Tanaka, T., Sakai, R., Mitani, K., Yoshida, M., Taniguchi, T., Yazaki, Y. and Hirai, H. 1996. A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. *MolCellBiol* 16:1283-1294.
67. Yoneyama, M., Suhara, W., Fukuhara, Y. and Fujita, T. 1997. Direct activation of a factor complex composed of IRF-3 and CBP/p300 by virus infection. *J.Interferon Cytokine Res.* 17:S53.

68. Zhang, J.J., Vinkemeier, U., Gu, W., Chakravarti, D., Horvath, C.M. and Darnell, J.E. 1996. Two contact regions between STAT1 and CBP/p300 in interferon γ signalling. *Proc.Natl.Acad.Sci.USA* 93:15092-15096.
- 5 69. Zhang, L. and Pagano, J.S. 1997. IRF-7, a new interferon regulatory factor associated with Epstein Barr Virus latency. *Mol.Cell.Biol.* 17:5748-5757.
70. Au, W.C., Moore, P.A., LaFleur, D.W., Tombal, B. and Pitha, P.M. (1998). Characterization of the interferon
- 10 regulatory factor-7 and its potential role in the transcription activation of interferon A gene. *J. Biol. Chem.* 273, 29210-29217.
71. Marie, I., Durbin, J.B. and Levy, D.E. (1998). Differential viral induction of distinct interferon- α genes by
- 15 positive feedback through interferon regulatory factor-7. *EMBO J.* 17, 6660-6669.
72. Nonkwello C, Ruf IK, Sample J. 1997. Interferon-independent and -induced regulation of Epstein-Barr Virus EBNA-1 gene transcription in Burkitt lymphoma. *J. Virol.* 71, 6887-
- 20 6897.

1/13

SEQUENCE LISTING

<110> THE SIR MORTIMER B. DAVIS-JEWISH GENERAL HOSPITAL

<120> HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR

PROTEINS

<130> IRF-3

<140>

<141>

<150> CA 2,234,588

<151> 1998-04-07

<160> 11

<170> PatentIn Ver. 2.0

<210> 1

<211> 1284

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1281)

<400> 1

atg	gga	acc	cca	aag	cca	cgg	atc	ctg	ccc	tgg	ctg	gtg	tcg	cag	ctg	48
Met	Gly	Thr	Pro	Lys	Pro	Arg	Ile	Leu	Pro	Trp	Leu	Val	Ser	Gln	Leu	
1				5					10					15		

gac	ctg	ggg	caa	ctg	gag	ggc	gtg	gcc	tgg	gtg	aac	aag	agc	cgc	acg	96
Asp	Leu	Gly	Gln	Leu	Glu	Gly	Val	Ala	Trp	Val	Asn	Lys	Ser	Arg	Thr	
	20						25						30			

cgc	ttc	cgc	atc	cct	tgg	aag	cac	ggc	cta	cgg	cag	gat	gca	cag	cag	144
Arg	Phe	Arg	Ile	Pro	Trp	Lys	His	Gly	Leu	Arg	Gln	Asp	Ala	Gln	Gln	
	35						40					45				

gag	gat	ttc	gga	atc	ttc	cag	gcc	tgg	gcc	gag	gcc	act	ggt	gca	tat	192
Glu	Asp	Phe	Gly	Ile	Phe	Gln	Ala	Trp	Ala	Glu	Ala	Thr	Gly	Ala	Tyr	
	50					55				60						

gtt	ccc	ggg	agg	gat	aag	cca	gac	ctg	cca	acc	tgg	aag	agg	aat	ttc	240
Val	Pro	Gly	Arg	Asp	Lys	Pro	Asp	Leu	Pro	Thr	Trp	Lys	Arg	Asn	Phe	
65					70					75					80	

F044030: 59624660

2/13

cgc tct gcc ctc aac cgc aaa gaa ggg ttg cgt tta gca gag gac cgg	288
Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg	
85 90 95	
agc aag gac cct cac gac cca cat aaa atc tac gag ttt gtg aac tca	336
Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser	
100 105 110	
gga gtt ggg gac ttt tcc cag cca gac acc tct ccg gac acc aat ggt	384
Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly	
115 120 125	
gga ggc agt act tct gat acc cag gaa gac att ctg gat gag tta ctg	432
Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu	
130 135 140	
ggt aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc cca agc ctg	480
Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu	
145 150 155 160	
gct gta gcc cct gag ccc tgc cct cag ccc ctg cgg agc ccc agc ttg	528
Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu	
165 170 175	
gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag aac cca ctg	576
Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu	
180 185 190	
aag cgg ctg ttg gtg ccg ggg gaa gag tgg gag ttc gag gtg aca gcc	624
Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu Val Thr Ala	
195 200 205	
ttc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc tgc ccg gag	672
Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser Cys Pro Glu	
210 215 220	
ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg ctg cct gga	720
Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr Leu Pro Gly	
225 230 235	
tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca gac agg gga	768
Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr Asp Arg Gly	
240 245 250 255	
gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt ggg gga ctg	816
Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly Gly Gly Leu	
260 265 270	
gct ctc tgg cgg gcc ggg cag tgg ctc tgg gcc cag cgg ctg ggg cac	864
Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg Leu Gly His	
275 280 285	
tgc cac aca tac tgg gca gtg agc gag gag ctg ctc ccc aac agc ggg	912
Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro Asn Ser Gly	
290 295 300	
cat ggg cct gat ggc gag gtc ccc aag gac aag gaa gga ggc gtg ttt	960
His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly Gly Val Phe	
305 310 315	
gac ctg ggg ccc ttc att gta gat ctg att acc ttc acg gaa gga agc	1008
Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr Glu Gly Ser	
320 325 330 335	
gga cgc tca cca cgc tat gcc ctc tgg ttc tgt gtg ggg gag tca tgg	1056
Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly Glu Ser Trp	
340 345 350	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

3/13

ccc cag gac cag ccg tgg acc aag agg ctc gtg atg gtc aag gtt gtg 1104
 Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val Lys Val Val
 355 360 365

ccc acg tgc ctc agg gcc ttg gta gaa atg gcc cgg gta ggg ggt gcc 1152
 Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val Gly Gly Ala
 370 375 380

tcc tcc ctg gag aat act gtg gac ctg cac att gac aac gac cac cca 1200
 Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn Asp His Pro
 385 390 395

ctc gac ctc gac gac gac cag tac aag gcc tac ctg cag gac ttg gtg 1248
 Leu Asp Leu Asp Asp Asp Gln Tyr Lys Ala Tyr Leu Gln Asp Leu Val
 400 405 410 415

gag ggc atg gat ttc cag ggc cct ggg gag agc tga 1284
 Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser
 420 425

<210> 2

<211> 427

<212> PRT

<213> Homo sapiens

<400> 2

Met Gly Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln Leu
 1 5 10 15

Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Val Asn Lys Ser Arg Thr
 20 25 30

Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp Ala Gln Gln
 35 40 45

Glu Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala Thr Gly Ala Tyr
 50 55 60

Val Pro Gly Arg Asp Lys Pro Asp Leu Pro Thr Trp Lys Arg Asn Phe
 65 70 75

Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg
 80 85 90 95

Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser
 100 105 110

Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly
 115 120 125

Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu
 130 135 140

Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu
 145 150 155

Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu
 160 165 170 175

Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu
 180 185 190

1104 1152 1200 1248 1284

<210> 3

<211> 13

<212> PRT

<213> Homo sapiens

<400> 3

Ile Ser Asn Ser His Pro Leu Ser Leu Thr Ser Asp Gln
1 5 10

<210> 4

<211> 4

<212> PRT

<213> Homo sapiens

<400> 4

5/13

Gly Ala Ala Ala
1

<210> 5

<211> 6

<212> PRT

<213> Homo sapiens

<400> 5

Gly Ala Ala Ala Asn Asn
1 5

<210> 6

<211> 15

<212> DNA

<213> Homo sapiens

<400> 6

ggaaaactga aaggg

15

<210> 7

<211> 30

<212> DNA

<213> Homo sapiens

<400> 7

gatcgggaaa gggaaaccga aactgaagcc

30

<210> 8

<211> 1512

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)..(1509)

<400> 8

atg	gcc	ttg	gct	cct	gag	agg	gca	gcc	cca	cgc	gtg	ctg	ttc	gga	gag	48
Met	Ala	Leu	Ala	Pro	Glu	Arg	Ala	Ala	Pro	Arg	Val	Leu	Phe	Gly	Glu	
1				5				10					15			

tgg	ctc	ctt	gga	gag	atc	agc	agc	ggc	tgc	tat	gag	ggg	ctg	cag	tgg	96
Trp	Leu	Leu	Gly	Glu	Ile	Ser	Ser	Gly	Cys	Tyr	Glu	Gly	Leu	Gln	Trp	
			20					25					30			

6/13

ctg gac gag gcc cgc acc tgt ttc cgc gtg ccc tgg aag cac ttc gcg	144
Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala	
35 40 45	
cgc aag gac ctg agc gag gcc gac gcg cgc atc ttc aag gcc tgg gct	192
Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala	
50 55 60	
gtg gcc cgc gcc agg tgg ccg cct agc agc agg gga ggt gcc ccg ccc	240
Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro	
65 70 75 80	
ccc gag gct gag act gcg gag cgc gcc gcc tgg aaa acc aac ttc cgc	288
Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg	
85 90 95	
tgc gca ctg cgc agc acg cgt cgc ttc gtg atg ctg cgg gat aac tcg	336
Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser	
100 105 110	
ggg gac ccg gcc gac ccg cac aag gtg tac gcg ctc agc cgg gag ctg	384
Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu	
115 120 125	
tgc tgg cga gaa gcc cca gcc acg gac cag act gag gca gag gcc ccc	432
Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro	
130 135 140	
gca gct gtc cca cca cca cag ggt ggg ccc cca ggg cca ttc ttg gca	480
Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala	
145 150 155 160	
cac aca cat gct gga ctc caa gcc cca gcc ccc ctc cct gcc cca gct	528
His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala	
165 170 175	
ggt gac aag ggg gac ctc ctg ctc cag gca gtg caa cag agc tgc ctg	576
Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu	
180 185 190	
gca gac cat ctg ctg aca gcg tca tgg ggg gca gat cca gtc cca acc	624
Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr	
195 200 205	
aag gct cct gga gag gga caa gaa ggg ctt ccc ctg act ggg gcc tgt	672
Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys	
210 215 220	
gct gga gcc cca ggg ctc cct gct ggg gag ctg tac ggg tgg gca gta	720
Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val	
225 230 235 240	
gag acg acc ccc agc ccc ggg ccc cag ccc gcg gca cta acg aca ggc	768
Glu Thr Thr Pro Ser Pro Gly Pro Gln Pro Ala Ala Leu Thr Thr Gly	
245 250 255	
gag gcc gcg gcc cca gag tcc ccg cac cag gca gag ccg tac ctg tca	816
Glu Ala Ala Ala Pro Glu Ser Pro His Gln Ala Glu Pro Tyr Leu Ser	
260 265 270	
ccc tcc cca agc gcc tgc acc gcg gtg caa gag ccc agc cca ggg gcg	864
Pro Ser Pro Ser Ala Cys Thr Ala Val Gln Glu Pro Ser Pro Gly Ala	
275 280 285	
ctg gac gtg acc atc atg tac aag ggc cgc acg gtg ctg cag aag gtg	912
Leu Asp Val Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val	
290 295 300	

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

7/13

gtg gga cac ccg agc tgc acg ttc cta tac ggc ccc cca gac cca gct 960
Val Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala
305 310 315 320

gtc cgg gcc aca gac ccc cag cag gta gca ttc ccc agc cct gcc gag 1008
Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala Glu
325 330 335

ctc ccg gac cag aag cag ctg cgc tac acg gag gaa ctg ctg cgg cac 1056
Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu Leu Arg His
340 345 350

gtg gcc cct ggg ttg cac ctg gag ctt cgg ggg cca cag ctg tgg gcc 1104
Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly Pro Gln Leu Trp Ala
355 360 365

cgg cgc atg ggc aag tgc aag gtg tac tgg gag gtg ggc gga ccc cca 1152
Arg Arg Met Gly Lys Cys Lys Val Tyr Trp Glu Val Gly Gly Pro Pro
370 375 380

ggc tcc gcc agc ccc tcc acc cca gcc tgc ctg ctg cct cgg aac tgt 1200
Gly Ser Ala Ser Pro Ser Thr Pro Ala Cys Leu Leu Pro Arg Asn Cys
385 390 395 400

gac acc ccc atc ttc gac ttc aga gtc ttc ttc caa gag ctg gtg gaa 1248
Asp Thr Pro Ile Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu
405 410 415

ttc cgg gca cgg cag cgc cgt ggc tcc cca cgc tat acc atc tac ctg 1296
Phe Arg Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu
420 425 430

ggc ttc ggg cag gac ctg tca gct ggg agg ccc aag gag aag agc ctg 1344
Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu
435 440 445

gtc ctg gtg aag ctg gaa ccc tgg ctg tgc cga gtg cac cta gag ggc 1392
Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu Glu Gly
450 455 460

acg cag cgt gag ggt gtg tct tcc ctg gat agc agc gac ctc gac ctc 1440
Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser Asp Leu Asp Leu
465 470 475 480

tgc ctg tcc agc gcc aac agc ctc tat gac gac atc gag tgc ttc ctt 1488
Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp Ile Glu Cys Phe Leu
485 490 495

atg gag ctg gag cag ccc gcc tag 1512
Met Glu Leu Glu Gln Pro Ala
500

<210> 9

<211> 503

<212> PRT

<213> Homo sapiens

<400> 9

Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu
1 5 10 15

Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp
20 25 30

8/13

Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala
 35 40 45
 Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala
 50 55 60
 Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro
 65 70 75 80
 Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg
 85 90 95
 Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser
 100 105 110
 Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu
 115 120 125
 Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro
 130 135 140
 Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala
 145 150 155 160
 His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala
 165 170 175
 Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu
 180 185 190
 Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr
 195 200 205
 Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys
 210 215 220
 Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val
 225 230 235 240
 Glu Thr Thr Pro Ser Pro Gly Pro Gln Pro Ala Ala Leu Thr Thr Gly
 245 250 255
 Glu Ala Ala Ala Pro Glu Ser Pro His Gln Ala Glu Pro Tyr Leu Ser
 260 265 270
 Pro Ser Pro Ser Ala Cys Thr Ala Val Gln Glu Pro Ser Pro Gly Ala
 275 280 285
 Leu Asp Val Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val
 290 295 300
 Val Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala
 305 310 315 320
 Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala Glu
 325 330 335
 Leu Pro Asp Gln Lys Gln Leu Arg Tyr Thr Glu Glu Leu Leu Arg His
 340 345 350
 Val Ala Pro Gly Leu His Leu Glu Leu Arg Gly Pro Gln Leu Trp Ala
 355 360 365
 Arg Arg Met Gly Lys Cys Lys Val Tyr Trp Glu Val Gly Gly Pro Pro
 370 375 380
 Gly Ser Ala Ser Pro Ser Thr Pro Ala Cys Leu Leu Pro Arg Asn Cys
 385 390 395 400

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

9/13

Asp Thr Pro Ile Phe Asp Phe Arg Val Phe Phe Gln Glu Leu Val Glu
 405 410 415
 Phe Arg Ala Arg Gln Arg Arg Gly Ser Pro Arg Tyr Thr Ile Tyr Leu
 420 425 430
 Gly Phe Gly Gln Asp Leu Ser Ala Gly Arg Pro Lys Glu Lys Ser Leu
 435 440 445
 Val Leu Val Lys Leu Glu Pro Trp Leu Cys Arg Val His Leu Glu Gly
 450 455 460
 Thr Gln Arg Glu Gly Val Ser Ser Leu Asp Ser Ser Asp Leu Asp Leu
 465 470 475 480
 Cys Leu Ser Ser Ala Asn Ser Leu Tyr Asp Asp Ile Glu Cys Phe Leu
 485 490 495
 Met Glu Leu Glu Gln Pro Ala
 500

<210> 10

<211> 1629

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1) .. (1626)

<400> 10

atg gcc ttg gct cct gag agg gca gcc cca cgc gtg ctg ttc gga gag	48
Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu	
1 5 10 15	
tgg ctc ctt gga gag atc agc agc ggc tgc tat gag ggg ctg cag tgg	96
Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp	
20 25 30	
ctg gac gag gcc cgc acc tgt ttc cgc gtg ccc tgg aag cac ttc gcg	144
Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala	
35 40 45	
cgc aag gac ctg agc gag gcc gac gcg cgc atc ttc aag gcc tgg gct	192
Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala	
50 55 60	
gtg gcc cgc ggc agg tgg ccg cct agc agc agg gga ggt ggc ccg ccc	240
Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro	
65 70 75 80	
ccc gag gct gag act gcg gag cgc gcc ggc tgg aaa acc aac ttc cgc	288
Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg	
85 90 95	
tgc gca ctg cgc agc acg cgt cgc ttc gtg atg ctg cgg gat aac tcg	336
Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser	
100 105 110	

1629 1628 1627 1626 1625 1624 1623 1622 1621 1620 1619 1618 1617 1616 1615 1614 1613 1612 1611 1610 1609 1608 1607 1606 1605 1604 1603 1602 1601 1600 1599 1598 1597 1596 1595 1594 1593 1592 1591 1590 1589 1588 1587 1586 1585 1584 1583 1582 1581 1580 1579 1578 1577 1576 1575 1574 1573 1572 1571 1570 1569 1568 1567 1566 1565 1564 1563 1562 1561 1560 1559 1558 1557 1556 1555 1554 1553 1552 1551 1550 1549 1548 1547 1546 1545 1544 1543 1542 1541 1540 1539 1538 1537 1536 1535 1534 1533 1532 1531 1530 1529 1528 1527 1526 1525 1524 1523 1522 1521 1520 1519 1518 1517 1516 1515 1514 1513 1512 1511 1510 1509 1508 1507 1506 1505 1504 1503 1502 1501 1500 1499 1498 1497 1496 1495 1494 1493 1492 1491 1490 1489 1488 1487 1486 1485 1484 1483 1482 1481 1480 1479 1478 1477 1476 1475 1474 1473 1472 1471 1470 1469 1468 1467 1466 1465 1464 1463 1462 1461 1460 1459 1458 1457 1456 1455 1454 1453 1452 1451 1450 1449 1448 1447 1446 1445 1444 1443 1442 1441 1440 1439 1438 1437 1436 1435 1434 1433 1432 1431 1430 1429 1428 1427 1426 1425 1424 1423 1422 1421 1420 1419 1418 1417 1416 1415 1414 1413 1412 1411 1410 1409 1408 1407 1406 1405 1404 1403 1402 1401 1400 1399 1398 1397 1396 1395 1394 1393 1392 1391 1390 1389 1388 1387 1386 1385 1384 1383 1382 1381 1380 1379 1378 1377 1376 1375 1374 1373 1372 1371 1370 1369 1368 1367 1366 1365 1364 1363 1362 1361 1360 1359 1358 1357 1356 1355 1354 1353 1352 1351 1350 1349 1348 1347 1346 1345 1344 1343 1342 1341 1340 1339 1338 1337 1336 1335 1334 1333 1332 1331 1330 1329 1328 1327 1326 1325 1324 1323 1322 1321 1320 1319 1318 1317 1316 1315 1314 1313 1312 1311 1310 1309 1308 1307 1306 1305 1304 1303 1302 1301 1300 1299 1298 1297 1296 1295 1294 1293 1292 1291 1290 1289 1288 1287 1286 1285 1284 1283 1282 1281 1280 1279 1278 1277 1276 1275 1274 1273 1272 1271 1270 1269 1268 1267 1266 1265 1264 1263 1262 1261 1260 1259 1258 1257 1256 1255 1254 1253 1252 1251 1250 1249 1248 1247 1246 1245 1244 1243 1242 1241 1240 1239 1238 1237 1236 1235 1234 1233 1232 1231 1230 1229 1228 1227 1226 1225 1224 1223 1222 1221 1220 1219 1218 1217 1216 1215 1214 1213 1212 1211 1210 1209 1208 1207 1206 1205 1204 1203 1202 1201 1200 1199 1198 1197 1196 1195 1194 1193 1192 1191 1190 1189 1188 1187 1186 1185 1184 1183 1182 1181 1180 1179 1178 1177 1176 1175 1174 1173 1172 1171 1170 1169 1168 1167 1166 1165 1164 1163 1162 1161 1160 1159 1158 1157 1156 1155 1154 1153 1152 1151 1150 1149 1148 1147 1146 1145 1144 1143 1142 1141 1140 1139 1138 1137 1136 1135 1134 1133 1132 1131 1130 1129 1128 1127 1126 1125 1124 1123 1122 1121 1120 1119 1118 1117 1116 1115 1114 1113 1112 1111 1110 1109 1108 1107 1106 1105 1104 1103 1102 1101 1100 1099 1098 1097 1096 1095 1094 1093 1092 1091 1090 1089 1088 1087 1086 1085 1084 1083 1082 1081 1080 1079 1078 1077 1076 1075 1074 1073 1072 1071 1070 1069 1068 1067 1066 1065 1064 1063 1062 1061 1060 1059 1058 1057 1056 1055 1054 1053 1052 1051 1050 1049 1048 1047 1046 1045 1044 1043 1042 1041 1040 1039 1038 1037 1036 1035 1034 1033 1032 1031 1030 1029 1028 1027 1026 1025 1024 1023 1022 1021 1020 1019 1018 1017 1016 1015 1014 1013 1012 1011 1010 1009 1008 1007 1006 1005 1004 1003 1002 1001 1000 999 998 997 996 995 994 993 992 991 990 989 988 987 986 985 984 983 982 981 980 979 978 977 976 975 974 973 972 971 970 969 968 967 966 965 964 963 962 961 960 959 958 957 956 955 954 953 952 951 950 949 948 947 946 945 944 943 942 941 940 939 938 937 936 935 934 933 932 931 930 929 928 927 926 925 924 923 922 921 920 919 918 917 916 915 914 913 912 911 910 909 908 907 906 905 904 903 902 901 900 899 898 897 896 895 894 893 892 891 890 889 888 887 886 885 884 883 882 881 880 879 878 877 876 875 874 873 872 871 870 869 868 867 866 865 864 863 862 861 860 859 858 857 856 855 854 853 852 851 850 849 848 847 846 845 844 843 842 841 840 839 838 837 836 835 834 833 832 831 830 829 828 827 826 825 824 823 822 821 820 819 818 817 816 815 814 813 812 811 810 809 808 807 806 805 804 803 802 801 800 799 798 797 796 795 794 793 792 791 790 789 788 787 786 785 784 783 782 781 780 779 778 777 776 775 774 773 772 771 770 769 768 767 766 765 764 763 762 761 760 759 758 757 756 755 754 753 752 751 750 749 748 747 746 745 744 743 742 741 740 739 738 737 736 735 734 733 732 731 730 729 728 727 726 725 724 723 722 721 720 719 718 717 716 715 714 713 712 711 710 709 708 707 706 705 704 703 702 701 700 699 698 697 696 695 694 693 692 691 690 689 688 687 686 685 684 683 682 681 680 679 678 677 676 675 674 673 672 671 670 669 668 667 666 665 664 663 662 661 660 659 658 657 656 655 654 653 652 651 650 649 648 647 646 645 644 643 642 641 640 639 638 637 636 635 634 633 632 631 630 629 628 627 626 625 624 623 622 621 620 619 618 617 616 615 614 613 612 611 610 609 608 607 606 605 604 603 602 601 600 599 598 597 596 595 594 593 592 591 590 589 588 587 586 585 584 583 582 581 580 579 578 577 576 575 574 573 572 571 570 569 568 567 566 565 564 563 562 561 560 559 558 557 556 555 554 553 552 551 550 549 548 547 546 545 544 543 542 541 540 539 538 537 536 535 534 533 532 531 530 529 528 527 526 525 524 523 522 521 520 519 518 517 516 515 514 513 512 511 510 509 508 507 506 505 504 503 502 501 500 499 498 497 496 495 494 493 492 491 490 489 488 487 486 485 484 483 482 481 480 479 478 477 476 475 474 473 472 471 470 469 468 467 466 465 464 463 462 461 460 459 458 457 456 455 454 453 452 451 450 449 448 447 446 445 444 443 442 441 440 439 438 437 436 435 434 433 432 431 430 429 428 427 426 425 424 423 422 421 420 419 418 417 416 415 414 413 412 411 410 409 408 407 406 405 404 403 402 401 400 399 398 397 396 395 394 393 392 391 390 389 388 387 386 385 384 383 382 381 380 379 378 377 376 375 374 373 372 371 370 369 368 367 366 365 364 363 362 361 360 359 358 357 356 355 354 353 352 351 350 349 348 347 346 345 344 343 342 341 340 339 338 337 336 335 334 333 332 331 330 329 328 327 326 325 324 323 322 321 320 319 318 317 316 315 314 313 312 311 310 309 308 307 306 305 304 303 302 301 300 299 298 297 296 295 294 293 292 291 290 289 288 287 286 285 284 283 282 281 280 279 278 277 276 275 274 273 272 271 270 269 268 267 266 265 264 263 262 261 260 259 258 257 256 255 254 253 252 251 250 249 248 247 246 245 244 243 242 241 240 239 238 237 236 235 234 233 232 231 230 229 228 227 226 225 224 223 222 221 220 219 218 217 216 215 214 213 212 211 210 209 208 207 206 205 204 203 202 201 200 199 198 197 196 195 194 193 192 191 190 189 188 187 186 185 184 183 182 181 180 179 178 177 176 175 174 173 172 171 170 169 168 167 166 165 164 163 162 161 160 159 158 157 156 155 154 153 152 151 150 149 148 147 146 145 144 143 142 141 140 139 138 137 136 135 134 133 132 131 130 129 128 127 126 125 124 123 122 121 120 119 118 117 116 115 114 113 112 111 110 109 108 107 106 105 104 103 102 101 100 99 98 97 96 95 94 93 92 91 90 89 88 87 86 85 84 83 82 81 80 79 78 77 76 75 74 73 72 71 70 69 68 67 66 65 64 63 62 61 60 59 58 57 56 55 54 53 52 51 50 49 48 47 46 45 44 43 42 41 40 39 38 37 36 35 34 33 32 31 30 29 28 27 26 25 24 23 22 21 20 19 18 17 16 15 14 13 12 11 10 9 8 7 6 5 4 3 2 1

10/13

ggg gac ccg gcc gac ccg cac aag gtg tac gcg ctc agc cgg gag ctg	384
Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu	
115 120 125	
tgc tgg cga gaa ggc cca ggc acg gac cag act gag gca gag gcc ccc	432
Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro	
130 135 140	
gca gct gtc cca cca cca cag ggt ggg ccc cca ggg cca ttc ttg gca	480
Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala	
145 150 155 160	
cac aca cat gct gga ctc caa gcc cca ggc ccc ctc cct gcc cca gct	528
His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala	
165 170 175	
ggt gac aag ggg gac ctc ctg ctc cag gca gtg caa cag agc tgc ctg	576
Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu	
180 185 190	
gca gac cat ctg ctg aca gcg tca tgg ggg gca gat cca gtc cca acc	624
Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr	
195 200 205	
aag gct cct gga gag gga caa gaa ggg ctt ccc ctg act ggg gcc tgt	672
Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys	
210 215 220	
gct gga ggc cca ggg ctc cct gct ggg gag ctg tac ggg tgg gca gta	720
Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val	
225 230 235 240	
gag acg acc ccc agc ccc act tct gat acc cag gaa gac att ctg gat	768
Glu Thr Thr Pro Ser Pro Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp	
245 250 255	
gag tta ctg ggt aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc	816
Glu Leu Leu Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro	
260 265 270	
cca agc ctg gct gta gcc cct gag ccc tgc cct cag ccc ctg cgg agc	864
Pro Ser Leu Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser	
275 280 285	
ccc agc ttg gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag	912
Pro Ser Leu Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu	
290 295 300	
aac cca ctg aag cgg ctg ttg gtg ccg ggg gaa gag tgg gag ttc gag	960
Asn Pro Leu Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu	
305 310 315 320	
gtg aca gcc ttc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc	1008
Val Thr Ala Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser	
325 330 335	
tgc ccg gag ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg	1056
Cys Pro Glu Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr	
340 345 350	
ctg cct gga tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca	1104
Leu Pro Gly Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr	
355 360 365	
gac agg gga gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt	1152
Asp Arg Gly Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly	
370 375 380	

10/13
 384
 432
 480
 528
 576
 624
 672
 720
 768
 816
 864
 912
 960
 1008
 1056
 1104
 1152

11/13

ggg gga ctg gct ctc tgg cgg gcc ggg cag tgg ctc tgg gcc cag cgg 1200
 Gly Gly Leu Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg
 385 390 395 400
 ctg ggg cac tgc cac aca tac tgg gca gtg agc gag gag ctg ctc ccc 1248
 Leu Gly His Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro
 405 410 415
 aac agc ggg cat ggg cct gat ggc gag gtc ccc aag gac aag gaa gga 1296
 Asn Ser Gly His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly
 420 425 430
 ggc gtg ttt gac ctg ggg ccc ttc att gta gat ctg att acc ttc acg 1344
 Gly Val Phe Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr
 435 440 445
 gaa gga agc gga cgc tca cca cgc tat gcc ctc tgg ttc tgt gtg ggg 1392
 Glu Gly Ser Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly
 450 455 460
 gag tca tgg ccc cag gac cag ccg tgg acc aag agg ctc gtg atg gtc 1440
 Glu Ser Trp Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val
 465 470 475 480
 aag gtt gtg ccc acg tgc ctc agg gcc ttg gta gaa atg gcc cgg gta 1488
 Lys Val Val Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val
 485 490 495
 ggg ggt gcc tcc tcc ctg gag aat act gtg gac ctg cac att gac aac 1536
 Gly Gly Ala Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn
 500 505 510
 gac cac cca ctc gac ctc gac gac gac cag tac aag gcc tac ctg cag 1584
 Asp His Pro Leu Asp Leu Asp Asp Asp Gln Tyr Lys Ala Tyr Leu Gln
 515 520 525
 gac ttg gtg gag ggc atg gat ttc cag gcc cct ggg gag agc tga 1629
 Asp Leu Val Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser
 530 535 540

<210> 11

<211> 542

<212> PRT

<213> Homo sapiens

<400> 11

Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu
 1 5 10 15
 Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp
 20 25 30
 Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala
 35 40 45
 Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala
 50 55 60
 Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro
 65 70 75 80
 Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg
 85 90 95

12/13

Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser
 100 105 110
 Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu
 115 120 125
 Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro
 130 135 140
 Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala
 145 150 155 160
 His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala
 165 170 175
 Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu
 180 185 190
 Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr
 195 200 205
 Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys
 210 215 220
 Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val
 225 230 235 240
 Glu Thr Thr Pro Ser Pro Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp
 245 250 255
 Glu Leu Leu Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro
 260 265 270
 Pro Ser Leu Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser
 275 280 285
 Pro Ser Leu Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu
 290 295 300
 Asn Pro Leu Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu
 305 310 315 320
 Val Thr Ala Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser
 325 330 335
 Cys Pro Glu Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr
 340 345 350
 Leu Pro Gly Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr
 355 360 365
 Asp Arg Gly Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly
 370 375 380
 Gly Gly Leu Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg
 385 390 395 400
 Leu Gly His Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro
 405 410 415
 Asn Ser Gly His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly
 420 425 430
 Gly Val Phe Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr
 435 440 445
 Glu Gly Ser Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly
 450 455 460

13/13

Glu	Ser	Trp	Pro	Gln	Asp	Gln	Pro	Trp	Thr	Lys	Arg	Leu	Val	Met	Val
465					470					475					480
Lys	Val	Val	Pro	Thr	Cys	Leu	Arg	Ala	Leu	Val	Glu	Met	Ala	Arg	Val
				485					490					495	
Gly	Gly	Ala	Ser	Ser	Leu	Glu	Asn	Thr	Val	Asp	Leu	His	Ile	Asp	Asn
			500					505					510		
Asp	His	Pro	Leu	Asp	Leu	Asp	Asp	Asp	Gln	Tyr	Lys	Ala	Tyr	Leu	Gln
		515					520					525			
Asp	Leu	Val	Glu	Gly	Met	Asp	Phe	Gln	Gly	Pro	Gly	Glu	Ser		
	530					535					540				

PCT/CA99/00314



10 Rec'd PCT/ATC 24 MAY 2001

09/647965

7

<110> Hiscott, John
Lin, Rongtuan

<120> HIGHLY ACTIVE FORMS OF INTERFERON
REGULATORY FACTOR PROTEINS

<130> A33606-PCT-USA 071235.0111

<140> US 09/647,965

<141> 2000-10-06

<150> PCT/CA99/00314

<151> 1999-04-07

<150> CA 2,234,588

<151> 1998-04-07

<160> 11

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 1284

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(1284)

<400> 1

atg	gga	acc	cca	aag	cca	cgg	atc	ctg	ccc	tgg	ctg	gtg	tcg	cag	ctg	48
Met	Gly	Thr	Pro	Lys	Pro	Arg	Ile	Leu	Pro	Trp	Leu	Val	Ser	Gln	Leu	
1				5				10						15		

gac	ctg	ggg	caa	ctg	gag	ggc	gtg	gcc	tgg	gtg	aac	aag	agc	cgc	acg	96
Asp	Leu	Gly	Gln	Leu	Glu	Gly	Val	Ala	Trp	Val	Asn	Lys	Ser	Arg	Thr	
			20				25						30			

cgc	ttc	cgc	atc	cct	tgg	aag	cac	ggc	cta	cgg	cag	gat	gca	cag	cag	144
Arg	Phe	Arg	Ile	Pro	Trp	Lys	His	Gly	Leu	Arg	Gln	Asp	Ala	Gln	Gln	
			35				40					45				

gag	gat	ttc	gga	atc	ttc	cag	gcc	tgg	gcc	gag	gcc	act	ggg	gca	tat	192
Glu	Asp	Phe	Gly	Ile	Phe	Gln	Ala	Trp	Ala	Glu	Ala	Thr	Gly	Ala	Tyr	
			50				55					60				

gtt	ccc	ggg	agg	gat	aag	cca	gac	ctg	cca	acc	tgg	aag	agg	aat	ttc	240
Val	Pro	Gly	Arg	Asp	Lys	Pro	Asp	Leu	Pro	Thr	Trp	Lys	Arg	Asn	Phe	
					70						75				80	

cgc	tct	gcc	ctc	aac	cgc	aaa	gaa	ggg	ttg	cgt	tta	gca	gag	gac	cgg	288
Arg	Ser	Ala	Leu	Asn	Arg	Lys	Glu	Gly	Leu	Arg	Leu	Ala	Glu	Asp	Arg	
				85					90						95	

agc Ser	aag Lys	gac Asp	cct Pro	cac His	gac Asp	cca Pro	cat His	aaa Lys	atc Ile	tac Tyr	gag Glu	ttt Phe	gtg Val	aac Asn	tca Ser	336
100105110																
gga Gly	gtt Val	ggg Gly	gac Asp	ttt Phe	tcc Ser	cag Gln	cca Pro	gac Asp	acc Thr	tct Ser	ccg Pro	gac Asp	acc Thr	aat Asn	ggt Gly	384
115120125																
gga Gly	ggc Gly	agt Ser	act Thr	tct Ser	gat Asp	acc Thr	cag Gln	gaa Glu	gac Asp	att Ile	ctg Leu	gat Asp	gag Glu	tta Leu	ctg Leu	432
130135140																
ggt Gly	aac Asn	atg Met	gtg Val	ttg Leu	gcc Ala	cca Pro	ctc Leu	cca Pro	gat Asp	ccg Pro	gga Gly	ccc Pro	cca Pro	agc Ser	ctg Leu	480
145150155160																
gct Ala	gta Val	gcc Ala	cct Pro	gag Glu	ccc Pro	tgc Cys	cct Pro	cag Gln	ccc Pro	ctg Leu	cgg Arg	agc Ser	ccc Pro	agc Ser	ttg Leu	528
165170175																
gac Asp	aat Asn	ccc Pro	act Thr	ccc Pro	ttc Phe	cca Pro	aac Asn	ctg Leu	ggg Gly	ccc Pro	tct Ser	gag Glu	aac Asn	cca Pro	ctg Leu	576
180185190																
aag Lys	cgg Arg	ctg Leu	ttg Leu	gtg Val	ccg Pro	ggg Gly	gaa Glu	gag Glu	tgg Trp	gag Glu	ttc Phe	gag Glu	gtg Val	aca Thr	gcc Ala	624
195200205																
ttc Phe	tac Tyr	cgg Arg	ggc Gly	cgc Arg	caa Gln	gtc Val	ttc Phe	cag Gln	cag Gln	acc Thr	atc Ile	tcc Ser	tgc Cys	ccg Pro	gag Glu	672
210215220																
ggc Gly	ctg Leu	cgg Arg	ctg Leu	gtg Val	ggg Gly	tcc Ser	gaa Glu	gtg Val	gga Gly	gac Asp	agg Arg	acg Thr	ctg Leu	cct Pro	gga Gly	720
225230235240																
tgg Trp	cca Pro	gtc Val	aca Thr	ctg Leu	cca Pro	gac Asp	cct Pro	ggc Gly	atg Met	tcc Ser	ctg Leu	aca Thr	gac Asp	agg Arg	gga Gly	768
245250255																
gtg Val	atg Met	agc Ser	tac Tyr	gtg Val	agg Arg	cat His	gtg Val	ctg Leu	agc Ser	tgc Cys	ctg Leu	ggt Gly	ggg Gly	gga Gly	ctg Leu	816
260265270																
gct Ala	ctc Leu	tgg Trp	cgg Arg	gcc Ala	ggg Gly	cag Gln	tgg Trp	ctc Leu	tgg Trp	gcc Ala	cag Gln	cgg Arg	ctg Leu	ggg Gly	cac His	864
275280285																
tgc Cys	cac His	aca Thr	tac Tyr	tgg Trp	gca Ala	gtg Val	agc Ser	gag Glu	gag Glu	ctg Leu	ctc Leu	ccc Pro	aac Asn	agc Ser	ggg Gly	912
290295300																
cat His	ggg Gly	cct Pro	gat Asp	ggc Gly	gag Glu	gtc Val	ccc Pro	aag Lys	gac Asp	aag Lys	gaa Glu	gga Gly	ggc Gly	gtg Val	ttt Phe	960
305310315320																
gac	ctg	ggg	ccc	ttc	att	gta	gat	ctg	att	acc	ttc	acg	gaa	gga	agc	1008

<400> 5

Gly Ala Ala Ala Asn Asn

1 5

<210> 6

<211> 15

<212> DNA

<213> Homo sapiens

<400> 6

ggaaaactga aaggg

15

<210> 7

<211> 30

<212> DNA

<213> Homo sapiens

<400> 7

gatcgggaaa gggaaaccga aactgaagcc

30

<210> 8

<211> 1512

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (1)...(1512)

<400> 8

atg gcc ttg gct cct gag agg gca gcc cca cgc gtg ctg ttc gga gag 48
Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu
1 5 10 15

tgg ctc ctt gga gag atc agc agc ggc tgc tat gag ggg ctg cag tgg 96
Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp
20 25 30

ctg gac gag gcc cgc acc tgt ttc cgc gtg ccc tgg aag cac ttc gcg 144
Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala
35 40 45

cgc aag gac ctg agc gag gcc gac gcg cgc atc ttc aag gcc tgg gct 192
Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala
50 55 60

gtg gcc cgc ggc agg tgg ccg cct agc agc agg gga ggt ggc ccg ccc 240
Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro
65 70 75 80

ccc gag gct gag act gcg gag cgc gcc ggc tgg aaa acc aac ttc cgc 288
Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg
85 90 95

tgc gca ctg cgc agc acg cgt cgc ttc gtg atg ctg cgg gat aac tcg 336

Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser
100 105 110

ggg gac ccg gcc gac ccg cac aag gtg tac gcg ctc agc cgg gag ctg 384
Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu
115 120 125

tgc tgg cga gaa ggc cca ggc acg gac cag act gag gca gag gcc ccc 432
Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro
130 135 140

gca gct gtc cca cca cca cag ggt ggg ccc cca ggg cca ttc ttg gca 480
Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala
145 150 155 160

cac aca cat gct gga ctc caa gcc cca ggc ccc ctc cct gcc cca gct 528
His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala
165 170 175

ggt gac aag ggg gac ctc ctg ctc cag gca gtg caa cag agc tgc ctg 576
 Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu
 180 185 190

gca gac cat ctg ctg aca gcg tca tgg ggg gca gat cca gtc cca acc 624
Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr
195 200 205

aag gct cct gga gag gga caa gaa ggg ctt ccc ctg act ggg gcc tgt 672
Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys
210 215 220

gct gga ggc cca ggg ctc cct gct ggg gag ctg tac ggg tgg gca gta 720
Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val
225 230 235 240

gag acg acc ccc agc ccc ggg ccc cag ccc gcg gca cta acg aca ggc 768
Glu Thr Thr Pro Ser Pro Gly Pro Gln Pro Ala Ala Leu Thr Thr Gly
245 250 255

gag gcc gcg gcc cca gag tcc ccg cac cag gca gag ccg tac ctg tca 816
Glu Ala Ala Ala Pro Glu Ser Pro His Gln Ala Glu Pro Tyr Leu Ser
260 265 270

ccc tcc cca agc gcc tgc acc gcg gtg caa gag ccc agc cca ggg gcg 864
Pro Ser Pro Ser Ala Cys Thr Ala Val Gln Glu Pro Ser Pro Gly Ala
275 280 285

ctg gac gtg acc atc atg tac aag ggc cgc acg gtg ctg cag aag gtg 912
Leu Asp Val Thr Ile Met Tyr Lys Gly Arg Thr Val Leu Gln Lys Val
290 295 300

gtg gga cac ccg agc tgc acg ttc cta tac ggc ccc cca gac cca gct 960
Val Gly His Pro Ser Cys Thr Phe Leu Tyr Gly Pro Pro Asp Pro Ala
305 310 315 320

gtc cgg gcc aca gac ccc cag cag gta gca ttc ccc agc cct gcc gag 1008
Val Arg Ala Thr Asp Pro Gln Gln Val Ala Phe Pro Ser Pro Ala Glu

[illegible]

Leu	Asp	Glu	Ala	Arg	Thr	Cys	Phe	Arg	Val	Pro	Trp	Lys	His	Phe	Ala
	35						40					45			
Arg	Lys	Asp	Leu	Ser	Glu	Ala	Asp	Ala	Arg	Ile	Phe	Lys	Ala	Trp	Ala
	50					55					60				
Val	Ala	Arg	Gly	Arg	Trp	Pro	Pro	Ser	Ser	Arg	Gly	Gly	Gly	Pro	Pro
65					70					75					80
Pro	Glu	Ala	Glu	Thr	Ala	Glu	Arg	Ala	Gly	Trp	Lys	Thr	Asn	Phe	Arg
				85					90					95	
Cys	Ala	Leu	Arg	Ser	Thr	Arg	Arg	Phe	Val	Met	Leu	Arg	Asp	Asn	Ser
			100					105					110		
Gly	Asp	Pro	Ala	Asp	Pro	His	Lys	Val	Tyr	Ala	Leu	Ser	Arg	Glu	Leu
	115						120					125			
Cys	Trp	Arg	Glu	Gly	Pro	Gly	Thr	Asp	Gln	Thr	Glu	Ala	Glu	Ala	Pro
	130					135					140				
Ala	Ala	Val	Pro	Pro	Pro	Gln	Gly	Gly	Pro	Pro	Gly	Pro	Phe	Leu	Ala
145					150					155					160
His	Thr	His	Ala	Gly	Leu	Gln	Ala	Pro	Gly	Pro	Leu	Pro	Ala	Pro	Ala
				165					170					175	
Gly	Asp	Lys	Gly	Asp	Leu	Leu	Leu	Gln	Ala	Val	Gln	Gln	Ser	Cys	Leu
		180						185					190		
Ala	Asp	His	Leu	Leu	Thr	Ala	Ser	Trp	Gly	Ala	Asp	Pro	Val	Pro	Thr
	195						200					205			
Lys	Ala	Pro	Gly	Glu	Gly	Gln	Glu	Gly	Leu	Pro	Leu	Thr	Gly	Ala	Cys
	210					215					220				
Ala	Gly	Gly	Pro	Gly	Leu	Pro	Ala	Gly	Glu	Leu	Tyr	Gly	Trp	Ala	Val
225					230					235					240
Glu	Thr	Thr	Pro	Ser	Pro	Gly	Pro	Gln	Pro	Ala	Ala	Leu	Thr	Thr	Gly
				245					250					255	
Glu	Ala	Ala	Ala	Pro	Glu	Ser	Pro	His	Gln	Ala	Glu	Pro	Tyr	Leu	Ser
			260					265					270		
Pro	Ser	Pro	Ser	Ala	Cys	Thr	Ala	Val	Gln	Glu	Pro	Ser	Pro	Gly	Ala
	275						280					285			
Leu	Asp	Val	Thr	Ile	Met	Tyr	Lys	Gly	Arg	Thr	Val	Leu	Gln	Lys	Val
	290					295					300				
Val	Gly	His	Pro	Ser	Cys	Thr	Phe	Leu	Tyr	Gly	Pro	Pro	Asp	Pro	Ala
305					310					315					320
Val	Arg	Ala	Thr	Asp	Pro	Gln	Gln	Val	Ala	Phe	Pro	Ser	Pro	Ala	Glu
				325					330					335	
Leu	Pro	Asp	Gln	Lys	Gln	Leu	Arg	Tyr	Thr	Glu	Glu	Leu	Leu	Arg	His
		340						345					350		
Val	Ala	Pro	Gly	Leu	His	Leu	Glu	Leu	Arg	Gly	Pro	Gln	Leu	Trp	Ala
	355							360				365			
Arg	Arg	Met	Gly	Lys	Cys	Lys	Val	Tyr	Trp	Glu	Val	Gly	Gly	Pro	Pro
	370					375					380				
Gly	Ser	Ala	Ser	Pro	Ser	Thr	Pro	Ala	Cys	Leu	Leu	Pro	Arg	Asn	Cys
385					390					395					400
Asp	Thr	Pro	Ile	Phe	Asp	Phe	Arg	Val	Phe	Phe	Gln	Glu	Leu	Val	Glu
				405					410					415	
Phe	Arg	Ala	Arg	Gln	Arg	Arg	Gly	Ser	Pro	Arg	Tyr	Thr	Ile	Tyr	Leu
		420					425						430		
Gly	Phe	Gly	Gln	Asp	Leu	Ser	Ala	Gly	Arg	Pro	Lys	Glu	Lys	Ser	Leu
	435						440					445			
Val	Leu	Val	Lys	Leu	Glu	Pro	Trp	Leu	Cys	Arg	Val	His	Leu	Glu	Gly
	450					455					460				
Thr	Gln	Arg	Glu	Gly	Val	Ser	Ser	Leu	Asp	Ser	Ser	Asp	Leu	Asp	Leu
465					470				475					480	
Cys	Leu	Ser	Ser	Ala	Asn	Ser	Leu	Tyr	Asp	Asp	Ile	Glu	Cys	Phe	Leu

Met Glu Leu Glu Gln Pro Ala
500

485

490

495

<210> 10
<211> 1629
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (1)...(1629)

<400> 10

atg gcc ttg gct cct gag agg gca gcc cca cgc gtg ctg ttc gga gag	48
Met Ala Leu Ala Pro Glu Arg Ala Ala Pro Arg Val Leu Phe Gly Glu	
1 5 10 15	
tgg ctc ctt gga gag atc agc agc ggc tgc tat gag ggg ctg cag tgg	96
Trp Leu Leu Gly Glu Ile Ser Ser Gly Cys Tyr Glu Gly Leu Gln Trp	
20 25 30	
ctg gac gag gcc cgc acc tgt ttc cgc gtg ccc tgg aag cac ttc gcg	144
Leu Asp Glu Ala Arg Thr Cys Phe Arg Val Pro Trp Lys His Phe Ala	
35 40 45	
cgc aag gac ctg agc gag gcc gac gcg cgc atc ttc aag gcc tgg gct	192
Arg Lys Asp Leu Ser Glu Ala Asp Ala Arg Ile Phe Lys Ala Trp Ala	
50 55 60	
gtg gcc cgc ggc agg tgg ccg cct agc agc agg gga ggt ggc ccg ccc	240
Val Ala Arg Gly Arg Trp Pro Pro Ser Ser Arg Gly Gly Gly Pro Pro	
65 70 75 80	
ccc gag gct gag act gcg gag cgc gcc ggc tgg aaa acc aac ttc cgc	288
Pro Glu Ala Glu Thr Ala Glu Arg Ala Gly Trp Lys Thr Asn Phe Arg	
85 90 95	
tgc gca ctg cgc agc acg cgt cgc ttc gtg atg ctg cgg gat aac tcg	336
Cys Ala Leu Arg Ser Thr Arg Arg Phe Val Met Leu Arg Asp Asn Ser	
100 105 110	
ggg gac ccg gcc gac ccg cac aag gtg tac gcg ctc agc cgg gag ctg	384
Gly Asp Pro Ala Asp Pro His Lys Val Tyr Ala Leu Ser Arg Glu Leu	
115 120 125	
tgc tgg cga gaa ggc cca ggc acg gac cag act gag gca gag gcc ccc	432
Cys Trp Arg Glu Gly Pro Gly Thr Asp Gln Thr Glu Ala Glu Ala Pro	
130 135 140	
gca gct gtc cca cca cca cag ggt ggg ccc cca ggg cca ttc ttg gca	480
Ala Ala Val Pro Pro Pro Gln Gly Gly Pro Pro Gly Pro Phe Leu Ala	
145 150 155 160	
cac aca cat gct gga ctc caa gcc cca ggc ccc ctc cct gcc cca gct	528
His Thr His Ala Gly Leu Gln Ala Pro Gly Pro Leu Pro Ala Pro Ala	

165	170	175	
ggt gac aag ggg gac ctc ctg ctc cag gca gtg caa cag agc tgc ctg Gly Asp Lys Gly Asp Leu Leu Leu Gln Ala Val Gln Gln Ser Cys Leu 180 185 190			576
gca gac cat ctg ctg aca gcg tca tgg ggg gca gat cca gtc cca acc Ala Asp His Leu Leu Thr Ala Ser Trp Gly Ala Asp Pro Val Pro Thr 195 200 205			624
aag gct cct gga gag gga caa gaa ggg ctt ccc ctg act ggg gcc tgt Lys Ala Pro Gly Glu Gly Gln Glu Gly Leu Pro Leu Thr Gly Ala Cys 210 215 220			672
gct gga ggc cca ggg ctc cct gct ggg gag ctg tac ggg tgg gca gta Ala Gly Gly Pro Gly Leu Pro Ala Gly Glu Leu Tyr Gly Trp Ala Val 225 230 235 240			720
gag acg acc ccc agc ccc act tct gat acc cag gaa gac att ctg gat Glu Thr Thr Pro Ser Pro Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp 245 250 255			768
gag tta ctg ggt aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc Glu Leu Leu Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro 260 265 270			816
cca agc ctg gct gta gcc cct gag ccc tgc cct cag ccc ctg cgg agc Pro Ser Leu Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser 275 280 285			864
ccc agc ttg gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag Pro Ser Leu Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu 290 295 300			912
aac cca ctg aag cgg ctg ttg gtg ccg ggg gaa gag tgg gag ttc gag Asn Pro Leu Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu 305 310 315 320			960
gtg aca gcc ttc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc Val Thr Ala Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser 325 330 335			1008
tgc ccg gag ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg Cys Pro Glu Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr 340 345 350			1056
ctg cct gga tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca Leu Pro Gly Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr 355 360 365			1104
gac agg gga gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt Asp Arg Gly Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly 370 375 380			1152
ggg gga ctg gct ctc tgg cgg gcc ggg cag tgg ctc tgg gcc cag cgg Gly Gly Leu Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg 385 390 395 400			1200

M 05 . 05 . 00
42

CLAIMS:

1. A modified interferon regulatory factor (IRF) protein, the protein comprising at least one modified serine or threonine phosphoacceptor site in the carboxy-terminus domain, with the proviso that where said IRF protein is IRF-3, said at least one modified phosphoacceptor site does not comprise Ser-385 or Ser-386.
2. The interferon regulatory factor (IRF) protein according to claim 1, wherein cytokine gene activation by the modified IRF is increased relative to cytokine gene activation by a corresponding wild type IRF protein.
3. The interferon regulatory factor (IRF) protein according to claim 1 or 2, wherein the modified IRF is an IRF-3 protein modified at at least one serine or threonine phosphoacceptor site.
4. The interferon regulatory factor (IRF) protein according to claim 1 or 2, wherein the modified IRF is an IRF-7 protein modified at at least one serine or threonine phosphoacceptor site.
5. The interferon regulatory factor (IRF) protein according to any one of claims 1 to 4, wherein the at least one modified phosphoacceptor site is modified by phosphorylation.

11.05.05.00
43

6. The interferon regulatory factor (IRF) protein according to any one of claims 1 to 4, wherein the at least one modified phosphoacceptor site comprises an amino acid residue having an acidic side chain.

5

7. The interferon regulatory factor (IRF) protein according to claim 6, wherein the amino acid residue is aspartic acid.

10 8. The interferon regulatory factor (IRF) protein according to claim 5, wherein the modified IRF is IRF-3 modified at a site selected from at least one of Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405.

15 9. The interferon regulatory factor (IRF) protein according to claim 8, wherein the modified IRF is IRF-3 modified at Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405 sites.

20 10. The interferon regulatory factor (IRF) protein according to claim 9, wherein the modified IRF comprises a carboxy-terminus domain of Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405 and an amino-terminus domain from IRF-7.

25 11. The interferon regulatory factor (IRF) protein according to claim 6 or 7, wherein the modified IRF is IRF-3

M05.05.00
44

ART 34 AMDT

modified at a site selected from at least one of Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405.

12. The interferon regulatory factor (IRF) protein
5 according to claim 11, wherein the modified IRF is IRF-3
modified at Ser-396, Ser-398, Ser-402, Thr-404 and Ser-405
sites.

13. The interferon regulatory factor (IRF) protein
10 according to claim 12 having SEQ ID NO. 2 (IRF-3 (5D)).

14. The interferon regulatory factor (IRF) protein
15 according to claim 12, wherein the modified IRF comprises a
carboxy-terminus domain of Ser-396, Ser-398, Ser-402, Thr-404
and Ser-405 and an amino-terminus domain from IRF-7.

15. The interferon regulatory factor (IRF) protein
according to claim 14, wherein the modified IRF has an amino-
terminal domain comprising residues 1 to 246 of IRF-7 and a
20 carboxy-terminal domain comprising residues 132 to 427 of IRF-3
modified by replacement each of Ser-396, Ser-398, Ser-402, Thr-
404 and Ser-405 by an aspartic acid residue.

16. The interferon regulatory factor (IRF) protein
25 according to claim 15 having SEQ ID NO. 11 (IRF-7(1-246)/ IRF-
3(5D)(132-427)).

45

17. The interferon regulatory factor (IRF) protein according to claim 5, wherein the modified IRF is IRF-7 modified at a site selected from at least one of Ser-477 and Ser-479.

5

18. The interferon regulatory factor (IRF) protein according to claim 17, wherein the modified IRF-7 is modified at Ser-477 and Ser-479 sites.

10 19. The interferon regulatory factor (IRF) protein according to claims 6 or 7, wherein the modified IRF is IRF-7 modified at a site selected from at least one of Ser-477 and Ser-479.

15 20. The interferon regulatory factor (IRF) protein according to claim 19, wherein the modified IRF-7 is modified at Ser-477 and Ser-479 sites.

21. The interferon regulatory factor (IRF) protein
20 according to claim 20 having SEQ ID NO. 9 (IRF-7(2D)).

22. A nucleotide sequence selected from:

(a) a first nucleotide sequence which encodes the interferon regulatory factor (IRF) protein according to any
25 one of claims 6, 7, 11 to 16, 19, 20 or 21, or

46

(b) a second nucleotide sequence that is

hybridizable under stringent conditions with the complement of the first nucleotide sequence, wherein said second nucleotide sequence encodes an IRF protein wherein at least one serine or threonine phosphoacceptor site comprises an amino acid residue having an acidic side chain.

23. The nucleotide sequence according to claim 22, having SEQ ID NO. 1.

24. The nucleotide sequence according to claim 22, having SEQ ID NO. 8.

25. The nucleotide sequence according to claim 22, having SEQ ID NO. 10.

26. A pharmaceutical composition comprising an effective amount of the interferon regulatory factor (IRF) protein according to any one of claims 1 to 21, together with a pharmaceutically acceptable carrier, for the treatment of a viral infection.

27. The pharmaceutical composition according to claim 26, wherein the viral infection is selected from an influenza infection, a herpes infection, a hepatitis infection and an HIV infection.

28. Use of the interferon regulatory factor (IRF) protein according to any one of claims 1 to 21 to activate a cytokine gene.

11.05.05.00
47

ART 34 AMDT
29. The use according to claim 28, wherein the cytokine gene is an interferon gene or a chemokine gene.

30. Use of the interferon regulatory factor (IRF) protein
5 according to any one of claims 1 to 21 in cancer treatment.

31. Use of the nucleotide sequence according to any one of claims 22 to 25 to modify a target cell of an organism.

10 32. A commercial package containing as an active pharmaceutical ingredient the pharmaceutical composition according to claim 26 together with instructions for its use for the treatment of a viral infection.

107650-59624960
15 33. The commercial package according to claim 32, wherein the viral infection is selected from an influenza infection, a herpes infection, a hepatitis infection and an HIV infection.

34. A commercial package containing as an active
20 pharmaceutical ingredient the interferon regulatory factor (IRF) protein according to any one of claims 1 to 21 together with instructions for its use for the treatment of cancer.

ART 34 AMDT

2/13

10

cgc tct gcc ctc aac cgc aaa gaa ggg ttg cgt tta gca gag gac cgg 288
 Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg
 85 90 95

agc aag gac cct cac gac cca cat aaa atc tac gag ttt gtg aac tca 336
 Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser
 100 105 110

gga gtt ggg gac ttt tcc cag cca gac acc tct ccg gac acc aat ggt 384
 Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly
 115 120 125

gga ggc agt act tct gat acc cag gaa gac att ctg gat gag tta ctg 432
 Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu
 130 135 140

20

ggt aac atg gtg ttg gcc cca ctc cca gat ccg gga ccc cca agc ctg 480
 Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu
 145 150 155 160

gct gta gcc cct gag ccc tgc cct cag ccc ctg cgg agc ccc agc ttg 528
 Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu
 165 170 175

gac aat ccc act ccc ttc cca aac ctg ggg ccc tct gag aac cca ctg 576
 Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu
 180 185 190

30

aag cgg ctg ttg gtg ccg ggg gaa gag tgg gag ttc gag gtg aca gcc 624
 Lys Arg Leu Leu Val Pro Gly Glu Glu Trp Glu Phe Glu Val Thr Ala
 195 200 205

ttc tac cgg ggc cgc caa gtc ttc cag cag acc atc tcc tgc ccg gag 672
 Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser Cys Pro Glu
 210 215 220

40

ggc ctg cgg ctg gtg ggg tcc gaa gtg gga gac agg acg ctg cct gga 720
 Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr Leu Pro Gly
 225 230 235 240

tgg cca gtc aca ctg cca gac cct ggc atg tcc ctg aca gac agg gga 768
 Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr Asp Arg Gly
 245 250 255

gtg atg agc tac gtg agg cat gtg ctg agc tgc ctg ggt ggg gga ctg 816
 Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly Gly Gly Leu
 260 265 270

50

gct ctc tgg cgg gcc ggg cag tgg ctc tgg gcc cag cgg ctg ggg cac 864
 Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg Leu Gly His
 275 280 285

tgc cac aca tac tgg gca gtg agc gag gag ctg ctc ccc aac agc ggg 912
 Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Pro Asn Ser Gly
 290 295 300

cat ggg cct gat ggc gag gtc ccc aag gac aag gaa gga ggc gtg ttt 960
 His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly Gly Val Phe
 305 310 315 320

60

gac ctg ggg ccc ttc att gta gat ctg att acc ttc acg gaa gga agc 1008
 Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr Glu Gly Ser
 325 330 335

gga cgc tca cca cgc tat gcc ctc tgg ttc tgt gtg ggg gag tca tgg 1056
 Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly Glu Ser Trp
 340 345 350

AMENDED SHEET

3/13

ART 34 AMEND

10

ccc cag gac cag ccg tgg acc aag agg ctc gtg atg gtc aag gtt gtg 1104
Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val Lys Val Val
355 360 365

ccc acg tgc ctc agg gcc ttg gta gaa atg gcc cgg gta ggg ggt gcc 1152
Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val Gly Gly Ala
370 375 380

tcc tcc ctg gag aat act gtg gac ctg cac att gac aac gac cac cca 1200
Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn Asp His Pro
385 390 395 400

ctc gac ctc gac gac gac cag tac aag gcc tac ctg cag gac ttg gtg 1248
Leu Asp Leu Asp Asp Asp Gln Tyr Lys Ala Tyr Leu Gln Asp Leu Val
405 410 415

gag ggc atg gat ttc cag ggc cct ggg gag agc tga 1284
Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser
420 425

20

<210> 2

<211> 427

<212> PRT

<213> Homo sapiens

<400> 2

Met Gly Thr Pro Lys Pro Arg Ile Leu Pro Trp Leu Val Ser Gln Leu
1 5 10 15

Asp Leu Gly Gln Leu Glu Gly Val Ala Trp Val Asn Lys Ser Arg Thr
20 25 30

Arg Phe Arg Ile Pro Trp Lys His Gly Leu Arg Gln Asp Ala Gln Gln
35 40 45

Glu Asp Phe Gly Ile Phe Gln Ala Trp Ala Glu Ala Thr Gly Ala Tyr
50 55 60

Val Pro Gly Arg Asp Lys Pro Asp Leu Pro Thr Trp Lys Arg Asn Phe
65 70 75 80

Arg Ser Ala Leu Asn Arg Lys Glu Gly Leu Arg Leu Ala Glu Asp Arg
85 90 95

Ser Lys Asp Pro His Asp Pro His Lys Ile Tyr Glu Phe Val Asn Ser
100 105 110

Gly Val Gly Asp Phe Ser Gln Pro Asp Thr Ser Pro Asp Thr Asn Gly
115 120 125

Gly Gly Ser Thr Ser Asp Thr Gln Glu Asp Ile Leu Asp Glu Leu Leu
130 135 140

Gly Asn Met Val Leu Ala Pro Leu Pro Asp Pro Gly Pro Pro Ser Leu
145 150 155 160

Ala Val Ala Pro Glu Pro Cys Pro Gln Pro Leu Arg Ser Pro Ser Leu
165 170 175

Asp Asn Pro Thr Pro Phe Pro Asn Leu Gly Pro Ser Glu Asn Pro Leu
180 185 190

60

AMENDED SHEET

ART 34 AMDT

MOS.05.00

4/13

10

20

30

40

50

Lys Arg Leu Val Pro Gly Glu Glu Trp Glu Phe Glu Val Thr Ala
195 200 205

Phe Tyr Arg Gly Arg Gln Val Phe Gln Gln Thr Ile Ser Cys Pro Glu
210 215 220

Gly Leu Arg Leu Val Gly Ser Glu Val Gly Asp Arg Thr Leu Pro Gly
225 230 235 240

Trp Pro Val Thr Leu Pro Asp Pro Gly Met Ser Leu Thr Asp Arg Gly
245 250 255

Val Met Ser Tyr Val Arg His Val Leu Ser Cys Leu Gly Gly Gly Leu
260 265 270

Ala Leu Trp Arg Ala Gly Gln Trp Leu Trp Ala Gln Arg Leu Gly His
275 280 285

Cys His Thr Tyr Trp Ala Val Ser Glu Glu Leu Leu Pro Asn Ser Gly
290 295 300

His Gly Pro Asp Gly Glu Val Pro Lys Asp Lys Glu Gly Gly Val Phe
305 310 315 320

Asp Leu Gly Pro Phe Ile Val Asp Leu Ile Thr Phe Thr Glu Gly Ser
325 330 335

Gly Arg Ser Pro Arg Tyr Ala Leu Trp Phe Cys Val Gly Glu Ser Trp
340 345 350

Pro Gln Asp Gln Pro Trp Thr Lys Arg Leu Val Met Val Lys Val Val
355 360 365

Pro Thr Cys Leu Arg Ala Leu Val Glu Met Ala Arg Val Gly Gly Ala
370 375 380

Ser Ser Leu Glu Asn Thr Val Asp Leu His Ile Asp Asn Asp His Pro
385 390 395 400

Leu Asp Leu Asp Asp Asp Gln Tyr Lys Ala Tyr Leu Gln Asp Leu Val
405 410 415

Glu Gly Met Asp Phe Gln Gly Pro Gly Glu Ser
420 425

<210> 3

<211> 13

<212> PRT

<213> Homo sapiens

<400> 3

Ile Ser Asn Ser His Pro Leu Ser Leu Thr Ser Asp Gln
1 5 10

<210> 4

<211> 4

<212> PRT

<213> Homo sapiens

<400> 4

444

AMENDED SHEET




FIG. 1

2/30




FIG. 2A




FIG. 2B

3/30




FIG. 3A

4/30




FIG. 3B




FIG. 4A

6/30




FIG. 4B

7/30




FIG. 5A
wtIRF-3




FIG. 5B
wtIRF-3




FIG. 5C
IRF-3(5A)




FIG. 5D
IRF-3(5A)




FIG. 5E
IRF-3(5D)




FIG. 5F
IRF-3(5D)



FIG. 5G
IRF-3(NES)




FIG. 5H
IRF-3(NES)

FIG. 5A-5H

8/30

IFN β -CAT




FIG. 6A

FIG. 6A: 596,496

9/30

IFN β -CAT




FIG. 6B

10/30

ISG15-CAT




FIG. 6C

FIG. 6C: 396/4960

11/30




FIG. 7A






FIG. 7B

12/30



13/30




FIG. 8A Endogenous IRF-3




FIG. 8B IRF-3ΔN




FIG. 8C IRF-3ΔN5A




FIG. 9A

15/30




FIG. 9B




FIG. 9C




FIG. 9D

17/30

```

      10      20      30      40
      *      *      *      *
ATG GGA ACC CCA AAG CCA CGG ATC CTG CCC TGG CTG GTG TCG CAG CTG
TAC CCT TGG GGT TTC GGT GCC TAG GAC GGG ACC GAC CAC AGC GTC GAC
M   G   T   P   K   P   R   I   L   P   W   L   V   S   Q   L>

50      60      70      80      90
*      *      *      *      *
GAC CTG GGG CAA CTG GAG GGC GTG GCC TGG GTG AAC AAG AGC CGC ACG
CTG GAC CCC GTT GAC CTC CCG CAC CGG ACC CAC TTG TTC TCG GCG TGC
D   L   G   Q   L   E   G   V   A   W   V   N   K   S   R   T>

100     110     120     130     140
*      *      *      *      *
CGC TTC CGC ATC CCT TGG AAG CAC GGC CTA CGG CAG GAT GCA CAG CAG
GCG AAG GCG TAG GGA ACC TTC GTG CCG GAT GCC GTC CTA CGT GTC GTC
R   F   R   I   P   W   K   H   G   L   R   Q   D   A   Q   Q>

150     160     170     180     190
*      *      *      *      *
GAG GAT TTC GGA ATC TTC CAG GCC TGG GCC GAG GCC ACT GGT GCA TAT
CTC CTA AAG CCT TAG AAG GTC CGG ACC CGG CTC CGG TGA CCA CGT ATA
E   D   F   G   I   F   Q   A   W   A   E   A   T   G   A   Y>

200     210     220     230     240
*      *      *      *      *
GTT CCC GGG AGG GAT AAG CCA GAC CTG CCA ACC TGG AAG AGG AAT TTC
CAA GGG CCC TCC CTA TTC GGT CTG GAC GGT TGG ACC TTC TCC TTA AAG
V   P   G   R   D   K   P   D   L   P   T   W   K   R   N   F>

250     260     270     280
*      *      *      *
CGC TCT GCC CTC AAC CGC AAA GAA GGG TTG CGT TTA GCA GAG GAC CGG
GCG AGA CGG GAG TTG GCG TTT CTT CCC AAC GCA AAT CGT CTC CTG GCC
R   S   A   L   N   R   K   E   G   L   R   L   A   E   D   R>

290     300     310     320     330
*      *      *      *      *
AGC AAG GAC CCT CAC GAC CCA CAT AAA ATC TAC GAG TTT GTG AAC TCA
TCG TTC CTG GGA GTG CTG GGT GTA TTT TAG ATG CTC AAA CAC TTG AGT
S   K   D   P   H   D   P   H   K   I   Y   E   F   V   N   S>

340     350     360     370     380
*      *      *      *      *
GGA GTT GGG GAC TTT TCC CAG CCA GAC ACC TCT CCG GAC ACC AAT GGT
CCT CAA CCC CTG AAA AGG GTC GGT CTG TGG AGA GGC CTG TGG TTA CCA
G   V   G   D   F   S   Q   P   D   T   S   P   D   T   N   G>

390     400     410     420     430
*      *      *      *      *
GGA GGC AGT ACT TCT GAT ACC CAG GAA GAC ATT CTG GAT GAG TTA CTG
CCT CCG TCA TGA AGA CTA TGG GTC CTT CTG TAA GAC CTA CTC AAT GAC
G   G   S   T   S   D   T   Q   E   D   I   L   D   E   L   L>

```

FIG. 10


[illegible]

FIG. 10
CONTINUED

[illegible]

FIG. 10
CONTINUED

20/30

**FIG. 11**

21/30

			10			20			30			40					
			*			*			*			*					
ATG	GCC	TTG	GCT	CCT	GAG	AGG	GCA	GCC	CCA	CGC	GTG	CTG	TTC	GGA	GAG		
TAC	CGG	AAC	CGA	GGA	CTC	TCC	CGT	CGG	GGT	GCG	CAC	GAC	AAG	CCT	CTC		
M	A	L	A	P	E	R	A	A	P	R	V	L	F	G	E>		
50			60			70			80			90					
*			*			*			*			*					
TGG	CTC	CTT	GGA	GAG	ATC	AGC	AGC	GGC	TGC	TAT	GAG	GGG	CTG	CAG	TGG		
ACC	GAG	GAA	CCT	CTC	TAG	TCG	TCG	CCG	ACG	ATA	CTC	CCC	GAC	GTC	ACC		
W	L	L	G	E	I	S	S	G	C	Y	E	G	L	Q	W>		
100			110			120			130			140					
*			*			*			*			*					
CTG	GAC	GAG	GCC	CGC	ACC	TGT	TTC	CGC	GTG	CCC	TGG	AAG	CAC	TTC	GCG		
GAC	CTG	CTC	CGG	GCG	TGG	ACA	AAG	GCG	CAC	GGG	ACC	TTC	GTG	AAG	CGC		
L	D	E	A	R	T	C	F	R	V	P	W	K	H	F	A>		
150			160			170			180			190					
*			*			*			*			*					
CGC	AAG	GAC	CTG	AGC	GAG	GCC	GAC	GCG	CGC	ATC	TTC	AAG	GCC	TGG	GCT		
GCG	TTC	CTG	GAC	TCG	CTC	CGG	CTG	CGC	GCG	TAG	AAG	TTC	CGG	ACC	CGA		
R	K	D	L	S	E	A	D	A	R	I	F	K	A	W	A>		
200			210			220			230			240					
*			*			*			*			*					
GTG	GCC	CGC	GGC	AGG	TGG	CCG	CCT	AGC	AGC	AGG	GGA	GGT	GGC	CCG	CCC		
CAC	CGG	GCG	CCG	TCC	ACC	GGC	GGA	TCG	TCG	TCC	CCT	CCA	CCG	GGC	GGG		
V	A	R	G	R	W	P	P	S	S	R	G	G	P	P>			
250			260			270			280								
*			*			*			*								
CCC	GAG	GCT	GAG	ACT	GCG	GAG	CGC	GCC	GGC	TGG	AAA	ACC	AAC	TTC	CGC		
GGG	CTC	CGA	CTC	TGA	CGC	CTC	GCG	CGG	CCG	ACC	TTT	TGG	TTG	AAG	GCG		
P	E	A	E	T	A	E	R	A	G	W	K	T	N	F	R>		
290			300			310			320			330					
*			*			*			*			*					
TGC	GCA	CTG	CGC	AGC	ACG	CGT	CGC	TTC	GTG	ATG	CTG	CGG	GAT	AAC	TCG		
ACG	CGT	GAC	GCG	TCG	TGC	GCA	GCG	AAG	CAC	TAC	GAC	GCC	CTA	TTG	AGC		
C	A	L	R	S	T	R	R	F	V	M	L	R	D	N	S>		
340			350			360			370			380					
*			*			*			*			*					
GGG	GAC	CCG	GCC	GAC	CCG	CAC	AAG	GTG	TAC	GCG	CTC	AGC	CGG	GAG	CTG		
CCC	CTG	GGC	CGG	CTG	GGC	GTG	TTC	CAC	ATG	CGC	GAG	TCG	GCC	CTC	GAC		
G	D	P	A	D	P	H	K	V	Y	A	L	S	R	E	L>		

FIG. 12

22/30

```

      390          400          410          420          430
      *          *          *          *          *
TGC TGG CGA GAA GGC CCA GGC ACG GAC CAG ACT GAG GCA GAG GCC CCC
ACG ACC GCT CTT CCG GGT CCG TGC CTG GTC TGA CTC CGT CTC CGG GGG
C   W   R   E   G   P   G   T   D   Q   T   E   A   E   A   P>

      440          450          460          470          480
      *          *          *          *          *
GCA GCT GTC CCA CCA CCA CAG GGT GGG CCC CCA GGG CCA TTC TTG GCA
CGT CGA CAG GGT GGT GGT GTC CCA CCC GGG GGT CCC GGT AAG AAC CGT
A   A   V   P   P   P   Q   G   G   P   P   G   P   F   L   A>

      490          500          510          520
      *          *          *          *
CAC ACA CAT GCT GGA CTC CAA GCC CCA GGC CCC CTC CCT GCC CCA GCT
GTG TGT GTA CGA CCT GAG GTT CGG GGT CCG GGG GAG GGA CGG GGT CGA
H   T   H   A   G   L   Q   A   P   G   P   L   P   A   P   A>

530          540          550          560          570
*          *          *          *          *
GGT GAC AAG GGG GAC CTC CTG CTC CAG GCA GTG CAA CAG AGC TGC CTG
CCA CTG TTC CCC CTG GAG GAC GAG GTC CGT CAC GTT GTC TCG ACG GAC
G   D   K   G   D   L   L   L   Q   A   V   Q   Q   S   C   L>

      580          590          600          610          620
      *          *          *          *          *
GCA GAC CAT CTG CTG ACA GCG TCA TGG GGG GCA GAT CCA GTC CCA ACC
CGT CTG GTA GAC GAC TGT CGC AGT ACC CCC CGT CTA GGT CAG GGT TGG
A   D   H   L   L   T   A   S   W   G   A   D   P   V   P   T>

      630          640          650          660          670
      *          *          *          *          *
AAG GCT CCT GGA GAG GGA CAA GAA GGG CTT CCC CTG ACT GGG GCC TGT
TTC CGA GGA CCT CTC CCT GTT CTT CCC GAA GGG GAC TGA CCC CGG ACA
K   A   P   G   E   G   Q   E   G   L   P   L   T   G   A   C>

      680          690          700          710          720
      *          *          *          *          *
GCT GGA GGC CCA GGG CTC CCT GCT GGG GAG CTG TAC GGG TGG GCA GTA
CGA CCT CCG GGT CCC GAG GGA CGA CCC CTC GAC ATG CCC ACC CGT CAT
A   G   G   P   G   L   P   A   G   E   L   Y   G   W   A   V>

      730          740          750          760
      *          *          *          *
GAG ACG ACC CCC AGC CCC GGG CCC CAG CCC GCG GCA CTA ACG ACA GGC
CTC TGC TGG GGG TCG GGG CCC GGG GTC GGG CGC CGT GAT TGC TGT CCG
E   T   T   P   S   P   G   P   Q   P   A   A   L   T   T   G>

```

FIG. 12
CONTINUED

23/30

770 780 790 800 810
* * * * *
GAG GCC GCG GCC CCA GAG TCC CCG CAC CAG GCA GAG CCG TAC CTG TCA
CTC CGG CGC CGG GGT CTC AGG GGC GTG GTC CGT CTC GGC ATG GAC AGT
E A A A P E S P H Q A E P Y L S>

820 830 840 850 860
* * * * *
CCC TCC CCA AGC GCC TGC ACC GCG GTG CAA GAG CCC AGC CCA GGG GCG
GGG AGG GGT TCG CGG ACG TGG CGC CAC GTT CTC GGG TCG GGT CCC CGC
P S P S A C T A V Q E P S P G A>

870 880 890 900 910
* * * * *
CTG GAC GTG ACC ATC ATG TAC AAG GGC CGC ACG GTG CTG CAG AAG GTG
GAC CTG CAC TGG TAG TAC ATG TTC CCG GCG TGC CAC GAC GTC TTC CAC
L D V T I M Y K G R T V L Q K V>

920 930 940 950 960
* * * * *
GTG GGA CAC CCG AGC TGC ACG TTC CTA TAC GGC CCC CCA GAC CCA GCT
CAC CCT GTG GGC TCG ACG TGC AAG GAT ATG CCG GGG GGT CTG GGT CGA
V G H P S C T F L Y G P P D P A>

970 980 990 1000
* * * *
GTC CGG GCC ACA GAC CCC CAG CAG GTA GCA TTC CCC AGC CCT GCC GAG
CAG GCC CGG TGT CTG GGG GTC GTC CAT CGT AAG GGG TCG GGA CGG CTC
V R A T D P Q Q V A F P S P A E>

1010 1020 1030 1040 1050
* * * * *
CTC CCG GAC CAG AAG CAG CTG CGC TAC ACG GAG GAA CTG CTG CGG CAC
GAG GGC CTG GTC TTC GTC GAC GCG ATG TGC CTC CTT GAC GAC GCC GTG
L P D Q K Q L R Y T E E L L R H>

1060 1070 1080 1090 1100
* * * * *
GTG GCC CCT GGG TTG CAC CTG GAG CTT CGG GGG CCA CAG CTG TGG GCC
CAC CGG GGA CCC AAC GTG GAC CTC GAA GCC CCC GGT GTC GAC ACC CGG
V A P G L H L E L R G P Q L W A>

1110 1120 1130 1140 1150
* * * * *
CGG CGC ATG GGC AAG TGC AAG GTG TAC TGG GAG GTG GGC GGA CCC CCA
GCC GCG TAC CCG TTC ACG TTC CAC ATG ACC CTC CAC CCG CCT GGG GGT
R R M G K C K V Y W E V G G P P>

FIG. 12
CONTINUED

[illegible]

FIG. 12
CONTINUED

25/30

10 20 30 40
* * * *
ATG GCC TTG GCT CCT GAG AGG GCA GCC CCA CGC GTG CTG TTC GGA GAG
TAC CGG AAC CGA GGA CTC TCC CGT CGG GGT GCG CAC GAC AAG CCT CTC
M A L A P E R A A P R V L F G E>

50 60 70 80 90
* * * * *
TGG CTC CTT GGA GAG ATC AGC AGC GGC TGC TAT GAG GGG CTG CAG TGG
ACC GAG GAA CCT CTC TAG TCG TCG CCG ACG ATA CTC CCC GAC GTC ACC
W L L G E I S S G C Y E G L Q W>

100 110 120 130 140
* * * * *
CTG GAC GAG GCC CGC ACC TGT TTC CGC GTG CCC TGG AAG CAC TTC GCG
GAC CTG CTC CGG GCG TGG ACA AAG GCG CAC GGG ACC TTC GTG AAG CGC
L D E A R T C F R V P W K H F A>

150 160 170 180 190
* * * * *
CGC AAG GAC CTG AGC GAG GCC GAC GCG CGC ATC TTC AAG GCC TGG GCT
GCG TTC CTG GAC TCG CTC CGG CTG CGC GCG TAG AAG TTC CGG ACC CGA
R K D L S E A D A R I F K A W A>

200 210 220 230 240
* * * * *
GTG GCC CGC GGC AGG TGG CCG CCT AGC AGC AGG GGA GGT GGC CCG CCC
CAC CGG GCG CCG TCC ACC GGC GGA TCG TCG TCC CCT CCA CCG GGC GGG
V A R G R W P P S S R G G G P P>

250 260 270 280
* * * *
CCC GAG GCT GAG ACT GCG GAG CGC GCC GGC TGG AAA ACC AAC TTC CGC
GGG CTC CGA CTC TGA CGC CTC GCG CGG CCG ACC TTT TGG TTG AAG GCG
P E A E T A E R A G W K T N F R>

290 300 310 320 330
* * * * *
TGC GCA CTG CGC AGC ACG CGT CGC TTC GTG ATG CTG CGG GAT AAC TCG
ACG CGT GAC GCG TCG TGC GCA GCG AAG CAC TAC GAC GCC CTA TTG AGC
C A L R S T R R F V M L R D N S>

FIG. 13

26/30

340	350	360	370	380
*	*	*	*	*
GGG GAC CCG GCC GAC CCG CAC AAG GTG TAC GCG CTC AGC CGG GAG CTG				
CCC CTG GGC CGG CTG GGC GTG TTC CAC ATG CGC GAG TCG GCC CTC GAC				
G D P A D P H K V Y A L S R E L>				
390	400	410	420	430
*	*	*	*	*
TGC TGG CGA GAA GGC CCA GGC ACG GAC CAG ACT GAG GCA GAG GCC CCC				
ACG ACC GCT CTT CCG GGT CCG TGC CTG GTC TGA CTC CGT CTC CGG GGG				
C W R E G P G T D Q T E A E A P>				
440	450	460	470	480
*	*	*	*	*
GCA GCT GTC CCA CCA CCA CAG GGT GGG CCC CCA GGG CCA TTC TTG GCA				
CGT CGA CAG GGT GGT GGT GTC CCA CCC GGG GGT CCC GGT AAG AAC CGT				
A A V P P P Q G G P P G P F L A>				
490	500	510	520	
*	*	*	*	
CAC ACA CAT GCT GGA CTC CAA GCC CCA GGC CCC CTC CCT GCC CCA GCT				
GTG TGT GTA CGA CCT GAG GTT CCG GGT CCG GGG GAG GGA CGG GGT CGA				
H T H A G L Q A P G P L P A P A>				
530	540	550	560	570
*	*	*	*	*
GGT GAC AAG GGG GAC CTC CTG CTC CAG GCA GTG CAA CAG AGC TGC CTG				
CCA CTG TTC CCC CTG GAG GAC GAG GTC CGT CAC GTT GTC TCG ACG GAC				
G D K G D L L L Q A V Q Q S C L>				
580	590	600	610	620
*	*	*	*	*
GCA GAC CAT CTG CTG ACA GCG TCA TGG GGG GCA GAT CCA GTC CCA ACC				
CGT CTG GTA GAC GAC TGT CGC AGT ACC CCC CGT CTA GGT CAG GGT TGG				
A D H L L T A S W G A D P V P T>				
630	640	650	660	670
*	*	*	*	*
AAG GCT CCT GGA GAG GGA CAA GAA GGG CTT CCC CTG ACT GGG GCC TGT				
TTC CGA GGA CCT CTC CCT GTT CTT CCC GAA GGG GAC TGA CCC CGG ACA				
K A P G E G Q E G L P L T G A C>				
680	690	700	710	720
*	*	*	*	*
GCT GGA GGC CCA GGG CTC CCT GCT GGG GAG CTG TAC GGG TGG GCA GTA				
CGA CCT CCG GGT CCC GAG GGA CGA CCC CTC GAC ATG CCC ACC CGT CAT				
A G G P G L P A G E L Y G W A V>				

FIG. 13
CONTINUED

F04G0001: 99024960

27/30

730 *	740 *	750 *	760 *
GAG ACG ACC CCC AGC CCC ACT TCT GAT ACC CAG GAA GAC ATT CTG GAT			
CTC TGC TGG GGG TCG GGG TGA AGA CTA TGG GTC CTT CTG TAA GAC CTA			
E T T P S P T S D T Q E D I L D>			
770 *	780 *	790 *	800 *
GAG TTA CTG GGT AAC ATG GTG TTG GCC CCA CTC CCA GAT CCG GGA CCC			
CTC AAT GAC CCA TTG TAC CAC AAC CGG GGT GAG GGT CTA GGC CCT GGG			
E L L G N M V L A P L P D P G P>			
820 *	830 *	840 *	850 *
CCA AGC CTG GCT GTA GCC CCT GAG CCC TGC CCT CAG CCC CTG CGG AGC			
GGT TCG GAC CGA CAT CGG GGA CTC GGG ACG GGA GTC GGG GAC GCC TCG			
P S L A V A P E P C P Q P L R S>			
870 *	880 *	890 *	900 *
CCC AGC TTG GAC AAT CCC ACT CCC TTC CCA AAC CTG GGG CCC TCT GAG			
GGG TCG AAC CTG TTA GGG TGA GGG AAG GGT TTG GAC CCC GGG AGA CTC			
P S L D N P T P F P N L G P S E>			
920 *	930 *	940 *	950 *
AAC CCA CTG AAG CGG CTG TTG GTG CCG GGG GAA GAG TGG GAG TTC GAG			
TTG GGT GAC TTC GCC GAC AAC CAC GGC CCC CTT CTC ACC CTC AAG CTC			
N P L K R L L V P G E E W E F E>			
970 *	980 *	990 *	1000 *
GTG ACA GCC TTC TAC CGG GGC CGC CAA GTC TTC CAG CAG ACC ATC TCC			
CAC TGT CGG AAG ATG GCC CCG GCG GTT CAG AAG GTC GTC TGG TAG AGG			
V T A F Y R G R Q V F Q Q T I S>			
1010 *	1020 *	1030 *	1040 *
TGC CCG GAG GGC CTG CGG CTG GTG GGG TCC GAA GTG GGA GAC AGG ACG			
ACG GGC CTC CCG GAC GCC GAC CAC CCC AGG CTT CAC CCT CTG TCC TGC			
C P E G L R L V G S E V G D R T>			
1060 *	1070 *	1080 *	1090 *
CTG CCT GGA TGG CCA GTC ACA CTG CCA GAC CCT GGC ATG TCC CTG ACA			
GAC GGA CCT ACC GGT CAG TGT GAC GGT CTG GGA CCG TAC AGG GAC TGT			
L P G W P V T L P D P G M S L T>			

FIG. 13
CONTINUED

28/30

1110 1120 1130 1140 1150
 * * * * *
 GAC AGG GGA GTG ATG AGC TAC GTG AGG CAT GTG CTG AGC TGC CTG GGT
 CTG TCC CCT CAC TAC TCG ATG CAC TCC GTA CAC GAC TCG ACG GAC CCA
 D R G V M S Y V R H V L S C L G>

1160 1170 1180 1190 1200
 * * * * *
 GGG GGA CTG GCT CTC TGG CGG GCC GGG CAG TGG CTC TGG GCC CAG CGG
 CCC CCT GAC CGA GAG ACC GCC CGG CCC GTC ACC GAG ACC CGG GTC GCC
 G G L A L W R A G Q W L W A Q R>

1210 1220 1230 1240
 * * * *
 CTG GGG CAC TGC CAC ACA TAC TGG GCA GTG AGC GAG GAG CTG CTC CCC
 GAC CCC GTG ACG GTG TGT ATG ACC CGT CAC TCG CTC CTC GAC GAG GGG
 L G H C H T Y W A V S E E L L P>

1250 1260 1270 1280 1290
 * * * * *
 AAC AGC GGG CAT GGG CCT GAT GGC GAG GTC CCC AAG GAC AAG GAA GGA
 TTG TCG CCC GTA CCC GGA CTA CCG CTC CAG GGG TTC CTG TTC CTT CCT
 N S G H G P D G E V P K D K E G>

1300 1310 1320 1330 1340
 * * * * *
 GGC GTG TTT GAC CTG GGG CCC TTC ATT GTA GAT CTG ATT ACC TTC ACG
 CCG CAC AAA CTG GAC CCC GGG AAG TAA CAT CTA GAC TAA TGG AAG TGC
 G V F D L G P F I V D L I T F T>

1350 1360 1370 1380 1390
 * * * * *
 GAA GGA AGC GGA CGC TCA CCA CGC TAT GCC CTC TGG TTC TGT GTG GGG
 CTT CCT TCG CCT GCG AGT GGT GCG ATA CGG GAG ACC AAG ACA CAC CCC
 E G S G R S P R Y A L W F C V G>

1400 1410 1420 1430 1440
 * * * * *
 GAG TCA TGG CCC CAG GAC CAG CCG TGG ACC AAG AGG CTC GTG ATG GTC
 CTC AGT ACC GGG GTC CTG GTC GGC ACC TGG TTC TCC GAG CAC TAC CAG
 E S W P Q D Q P W T K R L V M V>

1450 1460 1470 1480
 * * * *
 AAG GTT GTG CCC ACG TGC CTC AGG GCC TTG GTA GAA ATG GCC CGG GTA
 TTC CAA CAC GGG TGC ACG GAG TCC CGG AAC CAT CTT TAC CGG GCC CAT
 K V V P T C L R A L V E M A R V>

1490 1500 1510 1520 1530
 * * * * *
 GGG GGT GCC TCC TCC CTG GAG AAT ACT GTG GAC CTG CAC ATT GAC AAC
 CCC CCA CGG AGG AGG GAC CTC TTA TGA CAC CTG GAC GTG TAA CTG TTG
 G G A S S L E N T V D L H I D N>

FIG. 13
CONTINUED

1110 1120 1130 1140 1150
 1160 1170 1180 1190 1200
 1210 1220 1230 1240
 1250 1260 1270 1280 1290
 1300 1310 1320 1330 1340
 1350 1360 1370 1380 1390
 1400 1410 1420 1430 1440
 1450 1460 1470 1480
 1490 1500 1510 1520 1530

1540			1550			1560			1570			1580			
*			*			*			*			*			
GAC	CAC	CCA	CTC	GAC	CTC	GAC	GAC	GAC	CAG	TAC	AAG	GCC	TAC	CTG	CAG
CTG	GTG	GGT	GAG	CTG	GAG	CTG	CTG	CTG	GTC	ATG	TTC	CGG	ATG	GAC	GTC
D	H	P	L	D	L	D	D	D	Q	Y	K	A	Y	L	Q>
1590			1600			1610			1620						
*			*			*			*						
GAC	TTG	GTG	GAG	GGC	ATG	GAT	TTC	CAG	GGC	CCT	GGG	GAG	AGC	TGA	
CTG	AAC	CAC	CTC	CCG	TAC	CTA	AAG	GTC	CCG	GGA	CCC	CTC	TCG	ACT	
D	L	V	E	G	M	D	F	Q	G	P	G	E	S>		

FIG. 13
CONTINUED

30/30




FIG. 14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS

the specification of which

(check one) ☐ is attached hereto.

☒ was filed on October 6, 2000

as U.S. Application Serial No. 09/647,965

☐ was filed on _____

as PCT International Application No. _____

and (if applicable) was amended on _____

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information known to me which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §§1.56(a) and (b), which state:

- "(a) A patent by its very nature is affected with a public interest. The public interest is best served, and the most effective patent examination occurs when, at the time an application is being examined, the Office is aware of and evaluates the teachings of all information material to patentability. Each individual associated with the filing and prosecution of a patent application has a duty of candor and good faith in dealing with the Office, which includes a duty to disclose to the Office all information known to that individual to be material to patentability as defined in this section. The duty to disclose information exists with respect to each pending claim until the claim is cancelled or withdrawn from consideration, or the application becomes abandoned. Information material to the patentability that is cancelled or withdrawn from consideration need not be submitted if the information is not material to the patentability of any claim remaining under consideration in the application. There is no duty to submit information which is not material to the patentability of any existing claim. The duty to disclose all information known to be material to patentability is deemed to be satisfied if all information known to be material to patentability of any claim issued in a patent was cited by the Office or submitted to the Office in the manner prescribed by §§1.97(b)-(d) and 1.98. However, no patent will be granted on an application in connection with which fraud on the Office was practiced or attempted or the duty of disclosure was violated through bad faith or intentional misconduct. The Office encourages applicants to carefully examine:
- (1) prior art cited in search reports of a foreign patent office in a counterpart application,
 - (2) the closest information over which individuals associated with the filing or prosecution of a patent application believe any pending claim patentably defines, to make sure that any material information contained therein is disclosed to the Office.
- (b) Under this section, information is material to patentability when it is not cumulative to information already of record or being made of record in the application, and

T04290 " 5964950

- (1) It establishes, by itself or in combination with other information, a *prima facie* case of unpatentability of a claim; or
- (2) It refutes, or is inconsistent with, a position the applicant takes in:
 - (i) Opposing an argument of unpatentability relied on by the Office, or
 - (ii) Asserting an argument of patentability.

A *prima facie* case of unpatentability is established when the information compels a conclusion that a claim is unpatentable under the preponderance of evidence, burden-of-proof standard, giving each term in the claim its broadest reasonable construction consistent with the specification, and before any consideration is given to evidence which may be submitted in an attempt to establish a contrary conclusion of patentability."

I hereby claim foreign priority benefits under 35 United States Code, §119 and/or §365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate filed by me or my assignee disclosing the subject matter claimed in this application and having a filing date (1) before that of the application on which priority is claimed, or (2) if no priority claimed, before the filing of this application:

PRIOR FOREIGN APPLICATION(S)

<u>Number</u>	<u>Country</u>	<u>Filing Date</u> <i>(Month/Day/Year)</i>	<u>Date First</u> <u>Laid-open or</u> <u>Published</u>	<u>Date Patented</u> <u>or Granted</u>	<u>Priority Claimed?</u>
2234588	CA	04/07/98			

I hereby claim the benefit under 35 United States Code, §119(e) of any United States provisional application(s) listed below:

<u>Application Number</u>	<u>Filing Date</u>
---------------------------	--------------------

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56(a) which became available between the filing date of the prior application and the national or PCT international filing date of this application:

PRIOR U.S. OR PCT APPLICATION(S)

<u>Application No.</u>	<u>Filing Date</u> <i>(month/day/year)</i>	<u>Status</u> <i>(pending, abandoned, granted)</i>
PCT/CA99/00314	04/07/99	PENDING

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such wilful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following patent agents with full power of substitution, association and revocation to prosecute this application and/or international application and to transact all business in the Patent and Trademark Office connected therewith:

HUGH O'GORMAN (Reg. No. 26140)
R. ALLAN BRETT (Reg. No. 40476)
ROBERT D. GOULD (Reg. No. 27523)
THOMAS R. KELLY (Reg. No. 29244)
MICHAEL E. WHEELER (Reg. No. 29246)
DONALD F. PHENIX (Reg. No. 32528)
KOHJI SUZUKI (Reg. No. 44467)
R. JOHN HALEY (Reg. No. 29,502)
HANS KOENIG (Reg. No. 46474)
THUY HUONG NGUYEN (Reg. No. 47336)
FREDERICK C. CARVER (Reg. No. 17021)
JOSEPH D. GARON (Reg. No. 20420)
RONALD B. HILDRETH (Reg. No. 19,498)
ROBERT NEUNER (Reg. No. 24316)
RICHARD S. CLARK (Reg. No. 26154)
JAMES J. MAUNE (Reg. No. 26946)
HENRY TANG (Reg. No. 29705)
JOHN A. FOGARTY, JR. (Reg. No. 22348)
ROCHELLE K. SEIDE (Reg. No. 32300)
MARTA E. DELSIGNORE (Reg. No. 32689)

Customer No. 21003
BAKER BOTTS L.L.P.
30 Rockefeller Plaza
New York, New York
10112 U.S.A.
Tel: (212) 705-5000

1) INVENTOR'S SIGNATURE:

Date: JANUARY 8, 2001

Inventor's Name:

John

Hiscott

(First)

(Middle)

(Family Name)

Country of Citizenship:

CANADA

Residence:

Montreal, Quebec, Canada

(City, Province, Country)

Post Office Address:

132 Sheraton Drive, Montreal West, Quebec, Canada H4X 1N4

2) INVENTOR'S SIGNATURE:

Date: Jan. 8, 2001

Inventor's Name:

Rongtuan

Lin

(First)

(Middle)

(Family Name)

Country of Citizenship:

CANADA

Residence:

Montreal, Quebec, Canada

(City, Province, Country)

Post Office Address:

Apartment 17, 4455 Dupuis, Montreal, Quebec, Canada H3T 1E7

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27 (b)) - INDEPENDENT INVENTOR**

Docket No.
76023-36

Serial No.

09/647,965

Filing Date

10.06.00

Patent No.

Issue Date

Applicant/

Patentee: **HISCOTT, John and LIN, Rongtuan**

Invention:

HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS

As a below named inventor, I hereby declare that I qualify as an independent inventor as defined in 37 CFR 1.9(c) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled above and described in:

- ☐ the specification to be filed herewith.
☒ the application identified above.
☐ the patent identified above.

I have not assigned, granted, conveyed or licensed and am under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☐ No such person, concern or organization exists.
☒ Each such person, concern or organization is listed below.

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

FULL NAME **SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL**ADDRESS **3755 Chemin de la Côte-Ste-Catherine, Montreal, Quebec, H3T 1E2**☐ Individual☐ Small Business Concern☒ Nonprofit Organization

FULL NAME _____

ADDRESS _____

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME _____

ADDRESS _____

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

FULL NAME _____

ADDRESS _____

☐ Individual☐ Small Business Concern☐ Nonprofit Organization

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF INVENTOR John HISCOTT

SIGNATURE OF INVENTOR 

DATE: JANUARY 8, 2001

NAME OF INVENTOR Rongtuan LIN

SIGNATURE OF INVENTOR 

DATE: Jan. 8, 2001

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

NAME OF INVENTOR _____

SIGNATURE OF INVENTOR _____

DATE: _____

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) AND 1.27 (d)) - NONPROFIT ORGANIZATION**

Docket No.
76023-36

Serial No.

09/647,965

Filing Date

10/06/00

Patent No.

Issue Date

Applicant/

Patentee: **HISCOTT, John and LIN, Rongtuan**

Invention:

HIGHLY ACTIVE FORMS OF INTERFERON REGULATORY FACTOR PROTEINS

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: **SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL**ADDRESS OF ORGANIZATION: **3755 Chemin de la Cote-Ste-Catherine****Montreal, Quebec****H3T 1E2 Canada**

TYPE OF NONPROFIT ORGANIZATION:

- ☐ University or other Institute of Higher Education
- ☐ Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
- ☐ Nonprofit Scientific or Educational under Statute of State of The United States of America
Name of State: Citation of Statute:
- ☐ Would Qualify as Tax Exempt under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)) if Located in The United States of America
- ☒ Would Qualify as Nonprofit Scientific or Educational under Statute of State of The United States of America if Located in The United States of America
Name of State: Citation of Statute:

I hereby declare that the above-identified nonprofit organization qualifies as a nonprofit organization as defined in 37 C.F.R. 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☐ the specification to be filed herewith.
- ☒ the application identified above.
- ☐ the patent identified above.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the above-identified nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed on the next page and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9(c) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization to which I have assigned, granted, conveyed, or licensed or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- ☒ no such person, concern or organization exists.
☐ each such person, concern or organization is listed below.

FULL NAME

ADDRESS

☐

Individual

☐

Small Business Concern

☐

Nonprofit Organization

FULL NAME

ADDRESS

☐

Individual

☐

Small Business Concern

☐

Nonprofit Organization

FULL NAME

ADDRESS

☐

Individual

☐

Small Business Concern

☐

Nonprofit Organization

FULL NAME

ADDRESS

☐

Individual

☐

Small Business Concern

☐

Nonprofit Organization

Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING:

SAMUEL O. FREEDMAN, M.D.

TITLE IN ORGANIZATION:

SPECIAL ADVISOR

ADDRESS OF PERSON SIGNING:

ROOM B-115
 LADY DAVIS INSTITUTE FOR MEDICAL RESEARCH
 THE SIR MORTIMER B. DAVIS - JEWISH GENERAL HOSPITAL
 3755 CHEMIN DE LA CÔTE-STE-CATHERINE
 MONTREAL, QUEBEC H3T 1E2


SIGNATURE:

Samuel O. Freedman

DATE:

Jan 8, 2001

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ *Scanned copy is best available.* Drawing figures
1, 4B, 5A-5H, 7B, 7C, 8A-C, 9B-D,
are dark.